Cycloalkano-indole and -azaindole derivatives

Abstract

Cycloalcanoindole and -azaindole derivatives are prepared by reaction of appropriately substituted carboxylic acids with anmines. The cycloahloanindole and -azaindole derivatives are suitable as active compounds for medicaments, preferably antiatherosclerotic medicaments.

Description

[0001] The present invention relates to cycloalkano-indole and -azaindole derivatives, processes for their preparation and their use as medicaments, in particular as antiatherosclerotic medicarnents.

[0002] It is known that increased blood levels of triglycerides ypertriglyceridaemia) and cholesterol (hypercholesterolaemia) are associated with the genesis of atherosclerotic vessel wall changes and coronary heart diseases.

[0003] A distinctly increased risk of the development of coronary heart disease is moreover present if these two risk factors occur in combination, which is accompanied, in turn, with an overproduction of apolipoprotein B-100. There is therefore, as before, a great need to make available effective medicarnents for the control of atherosclerosis and coronary heart diseases.

[0004] The present invention relates to cycloalkano-indole and -azaindole derivatives of the general fonnula (I) 1

[0005] in which

[0006] R1 and R2, including the double bond connecting therm, together form a phenyl or pyridyl ring or a ring of the formula 2

[0007] wherein

[0008] R8 denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,

[0009] R3 and R4, including the double bond comuecting them, together form a phenyl ring or a 4- to 8-membered cycloaukene or oxocycloalkene radical,

[0010] all ring systems mentioned under R1/R2 and R3/R4 optionally being substituted up to 3 times by identical or different halogen, trifluoromethyl, carboxyl or hydroxyl substituents, by straight-chain or branched alk-oxy or alkoxycarbonyl each having up to 6 carbon atoms or by straiht-chain or branched atlkl having up to 6 carbon atoms, which, for its part, can be substituted by hydroxyl or by straight-chain or branched alkoxt having up to 4 carbon atoms,

[0011] D represents hydrogen, cycloalkyl having 4 to 12 carbon atoms or straight-chain or branched alkvl having up to 12 carbon atoms,

[0012] E represents the —CO— or —CS— group,

[0013] L represents an oxygen or sulphur atom or a group of the formula —NR9,

[0014] wherein

[0015] R9 denotes hydrogen or straight-chain or branched alkyl having up to 6 catbon atoms, which is optionally substituted by hydroxyl or phenyl,

[0016] R5 represents phenyl or a 5- to 7-membered sated or unsaturated heterocycle having up to 3 heteroatoms from the series consisting of S, N and/or O, the cycles optionally being substituted up to 3 times by identical or different nitro, carboxyl, halogen or cyano substituents or by straight-chain or branched alkenyl or alkoxycarbonyl each having up to 6 carbon atoms or by staight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by hydroxyl, carboxyl or by straighthain or branched alkoxy or alkoxycarbonyl each having up to 6 carbon atoms, and/or the cycles optionally being substituted by a group of the formula —OR10 or —NR11R12,

[0017] wherein

[0018] R10 denotes hydrogen or straight-chain or branched alkyl or alkenyl each having up to 6 carbon atoms,

[0019] R11 and R12 are identical or different and denote phenyt, hydrogen or straight-chain or branched alkyl having up to 6 carbon atoms or straighthain or branched acyl having up to 8 carbon atoms, which is optionally substituted by a group of the formula —NR13R14,

[0020] wherein

[0021] R13 and R14 are identical or different and denote hydrogen or straight-chain or branched acyl having up to 8 carbon atoms,

[0022] R6 represents hydrogen, carboxyl or straightmhain or branched alkoxycarbonyl having up to 5 carbon atoms, or represents straightchain or branched allkl having up to 6 carbon atoms, which is optionally substituted by hydroxyl or by a group of the formula —O—CO—R15,

[0023] wherein

[0024] R15 denotes phenyl which is optionally substituted up to 3 times by identical or different halogen or hydroxyl substituents or by straight-chain or branched allyl having up to 5 carbon atoms, or straiit-chain or branched allyl or alkenyrl each havling up to 22 carbon atoms, each of which is optionally substituted by a group of the formula —OR6,

[0025] wherein

[0026] R16 is hydrogen, benzyl, triphenylmethyl or straighthain or branched acyl having up to 6 carbon atoms,

[0027] R7 represents hydrogen or

[0028] R6 and R7 together represent the group of the formula ═O,

[0029] if appropriate in an isomeric fonrl and their salts.

[0030] The cycloalkanU indole and -azaindole derivatives according to the invention can also be present in the form of their salts. In general, salts with organic or inorganic bases or acids may be mentioned here.

[0031] In the context of the present invention, physiologically acceptable salts are preferred. Physiologically acceptable salts of the compounds according to the invention can be salts of the substances according to the invention with mineral acids, carboxylic acids or sulphonic acids. Particularly preferred salts are, for example, those with hydrochloric acid, hydrobrornic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, funric acid, maleic acid or benzoic acid.

[0032] Physiologically acceptable salts can also be metal or ammonium salts of the compounds according to the invention which have a free carboxyl group. Particularly preferred salts are, for example, sodium potassium magnesium or calcium salts, and also ammonium salts which are derived from ammonia, or organic amines, such as, for example ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylarnine, dimethylaminoethanol, arginine, lysine, ethylenediamnine or 2-phenylethylamnine.

[0033] Including the double bond of parent structure, the cycloalkene radical (R3/R4) in the context of the invention in general represents a 4 to 8-membered hydrocarbon radical, preferably a 5- to 8-membered hydrocarbon radical, for example a cyclobutene, cyclopentene, cyclohexene, cycloheptene or cyclooctene radical. The cyclopentene, cyclohexene, cyclooctene or cycloheptene radicals are preferred

[0034] Heterocycle (R5) in the context of the invention in general represents a saturated or unsaturated 5- to 7-membered heterocycle, preferably a 5- to 6-membered heterocycle, which can contain up to 3 heteroatoms from the series consisting of S, N and/or O. Examples vhich may be mentioned are: pyridyl, thienyl, finl, pyirolyl, thiazolyl, oxazolyl, imidazolyl, morpholinyl or piperidyl. Pyridyl and thienyl are preferred.

[0035] The compounds according to the invention can exist in stereoisomeric forms which either behave as image and mirror image (enantiomers), or do which do not behave as image and mirror image (diastereomers). The invention relates both to the enantiomers and diastereomers and their respective mixwures. These mixtres of the enantiomers and diastereomers can be separated in a known manner into the stereoisomerically uniform constituents.

[0036] Preferred compounds of the general formula (I) are those

[0037] in wich

[0038] R1 and R2, including the double bond connecting them, together form a phenyl or pyridyl ring or a ring of the formula 3

[0039] wherein

[0040] R8 denotes hydrogen or strighthain or branched alkyl having up to 3 carbon atoms,

[0041] R3 and R4, including the double bond connecting them, together form a phenyl ring or a cyclopentene, cyclohexene, cycloheptene, cyclooctene, oxocyclopentene, oxocyclohexene, oxocycloheptene or oxocyclooctene radical,

[0042] all ring systems mentioned under R1/R2 and R3/R4 optionally being substituted up to 2 times by identical or different fluorine, chlorine, bromine, trifluoromethyl, carboxyl or hydroxil substituents, by straight-chain or branched alkoxy or alkoxycarbonyl each having up to 4 carbon atoms or by straight-chain or branched alkyl having up to 4 carbon atoms, which, in tun, can be substituted by hvdroxl or by straight-chain or branched alkoxy having up to 3 carbon atoms.

[0043] D represents hydrogn, cyclobutrl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or straight-chain or branched alkyl having up to 10 carbon atoms,

[0044] E represents the —CO— or —CS— group,

[0045] L represents an ogen or sulphur atom or represents a group of the formufa —NR9,

[0046] wherein

[0047] R9 denotes hydrogen or staighthain or branched alkyl having up to 5 carbon atomns, which is optionally substituted by hydroxyl or phenyl,

[0048] R5 represents phenyl, pyridyl, firyl, thienyl or imidazolyl, each of wich is optionally substituted up to 2 times by identical or different nitro, carboxyl, 5 fluorine, chlorine, bromine or cyano substituents, by straighthain or branched alkenyl or alkoxy carbonyl each having up to 4 carbon atoms or by straight-chain or branched abkyl having up to 5 carbon atoms, which is optionally substituted by hydroxyl, carboxyl or by staight-chain or branched alkoxy or alkoxycarbonyl each having up to 5 carbon atoms, and/or the cycles are optionally substituted by a group of the formula —OR10 or —NR11R12,

[0049] wherein

[0050] R10 denotes hydrogen or straight-chain or branched alkyl or alkenyl each having up to 4 carbon atoms,

[0051] R11 and R12 are identical or different and denote phenyl, hydrogen or straight-chain or branched alk71 having up to 5 carbon atoms or denote straight-chain or branched acyl having up to 6 carbon atoms, which is optionally substituted by a group of the formula —NR13R14,

[0052] wherein

[0053] R13 and R14 are identical or different and denote hydrogen or straight-chain or branched acyl having up to 6 carbon atoms,

[0054] R6 represents hydrogen carboxyl or straight-chain or branched alkoxycarbonyl having up to 4 carbon atoms, or represents straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted by hydroxyl or by a group of the formula —O—CO—R15,

[0055] wherein

[0056] R15 denotes phenyl which is optionally substituted up to 3 times by identical or different fluorine, chlorine, bromine or hydroxyl substituents or by straicthain or branched alkyl having up to 4 carbon atoms, or straighthain or branched alkyl or alkenyl each having up to 20 carbon atoms, each of which is optionally substituted by a group of the formula —OR16,

[0057] wherein

[0058] R16 is hydrogen, benryl, triphenylmethyl or straight-chain or branched acyl having up to 5 carbon atoms,

[0059] R7 represents hydrogen or

[0060] R6 and R7 together represent the group of the formula ═O,

[0061] if appropriate in an isomeric form, and their salts.

[0062] Particularly preferred compounds of the general formula (I) are those

[0063] in which

[0064] R1 and R2, including the double bond connecting them, together form a phenyl or pyridyl ring or a ring of the formula 4

[0065] wherein

[0066] R8 denotes hydrogen or methyl,

[0067] R3 and R4, including the double bond connecting therm, together form a phenyl ring or a cyclopentene, cyclohexene, cycloheptene, cyclooctene, oxocyclopentene, oxocyclohexene, oxocycloheptene or oxocyclooctene radical,

[0068] all ring systems mentioned under R1/R2 and R3/R4 optionally being substituted up to 2 times by identical or different fluorine, chlorine, bromine, trifluoromethy,l, carboxyl or hydroxyl substituents, by straight-chain or branched alkoxy or alkoxycarbonyl each having up to 3 carbon atoms or by straight-chain or branched aLkyl having up to 3 carbon atoms, which, for its part, can be substituted by hydroxyl, methoxy or ethoxy,

[0069] D represents hydrogen, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or straight-chain or branched alkyl having up to 6 carbon atomns,

[0070] E represents the —CO— or —CS— group,

[0071] L represents an oxygen or sulphur atom or represents a group of the formula —NR9,

[0072] wherein

[0073] R9 denotes hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms, which is optionally substituted by hydroxyl or phenyl,

[0074] R5 represents phenyl, pyridyl or thienyl, each of which is optionally substituted up to 2 times by identical or different nitro, carboxyl, fluorine, chlorine, brornine or cyano substituents, by straightchain or branched alkenyl or alkoxycarbonyl each having up to 3 carbon atoms or by straight-chain or branched alkcyl having up to 4 carbon atoms, which is optionally substituted by hydroxyl, carboxyl or by straight-chain or branched alkoxy or alkoxycarbonyl each having up to 4 carbon atoms, and/or the cycles are optionally substituted by a group of the formula —OR10 or —NR11R12,

[0075] wherein

[0076] R10 denotes hydrogen or straight-chain or branched alkyl or alkenyl each having up to 3 carbon atoms,

[0077] R11 and R12 are identical or different and denote phenyl, hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms or denote straight-chain or branched acyl having up to 5 carbon atoms, which is optionally substituted by a group of the formula —NR13R14,

[0078] wherein

[0079] R13 and R14 are identical or different and denote hydrogen or straight-chain or branched acyl having up to 5 carbon atoms,

[0080] R6 represents hydrogen, carboxyl or straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms, or represents straight-chain or branched alkyl having up to 4 carbon atoms, i=which is optionally substituted. by hydroxyl or by a group of the formula —O—CO—R15,

[0081] wherein

[0082] R15 denotes phenyl which is optionally substituted up to 3 times by identical or different straight-chain or branched alkyl having up to 3 carbon atomns, or denotes straight-chain or branched alkyl or alkenyl each having up to 19 carbon atoms, each of which is optionally substituted by a group of the formula —OR16,

[0083] wherein

[0084] R16 denotes hydrogen, beneyl, triphenylmethyl or straighthain or branched acyl having up to 4 carbon atoms,

[0085] R7 represents hydrogen or

[0086] R6 and R7 together represent the group of the formula ═O,

[0087] if appropriate in an isomeric form, and their salts.

[0088] A process for the preparation of the compounds of the general formula (I) according to the invention has additionally been found, characterized in that carboylic acids of the general formula (II) 5

[0089] in which

[0090] R1, R2, R3, R4 and D have the meaning indicated, are amidated using compounds of the general formula (III) 6

[0091] in which

[0092] R5 has the meaning indicated

[0093] and

[0094] R17 has the indicated mearnig of R6, but does not represent carboxl,

[0095] in an inert solvent and in the presence of bases and/or auxiliaries,

[0096] and, if appropriate, functional groups are varied by hydrolysis, esterification or reduction.

[0097] The process accordina to the invention can be illustrated by the following reaction scheme: 7

[0098] Suitable solvents for the arnidation are in this case inert organic solvents A,,ich do not change under the reaction conditions. These include ethers, such as diethyl ether or tetrydroflrn halogenohydrcarbons such as dichioromethane, trichioromethane, tetrachioromethane, trichioroetane, tetrachloroethane, 1 ,2-dichloroethane or trichloroethylene, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or petroleum fractions, nitromethane, dimethylformmde, acetone, acetonitrile or hexarhethylphosphoramide. It is also possible to employ mixtures of the solvents. Dichloromethane, tetrahydroftu acetone and dimethylfonnrnde are particularly preferred.

[0099] Bases which can be employed for the process according to the invention are in general inorganic or organc bases. These preferaly include alkai metal hydroxides such as, for examle, sodium hydroxide or potassium hydroxide, alaine earth metal hydroxides, such as, for examnple, barium hydroxide, alkai metal carbonates such as sodium carbonate or potassium carbonate, alkaline earth metal carbonates such as calcium carbonate, or alkali metal alkoxides such as sodium or potassium methoxide, sodium or potassium ethoxide or potassium tert-butoxide, or organic amines (trialkyl(C1-C6)amines) such as triethylamine, or heterocycles such as 1,4diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), pyridine, diaminopyridine, methylpiperidine or morpholine. It is also possible to employ alkali metals such as sodium and their hydrides such as sodium hydride as bases. Sodium and potassium carbonate and triethylamnine are preferred.

[0100] The base is employed in an amount from 1 mol to 5 mol, preferably from 1 mol to 3 mol, relative to 1 mol of the compound of the general formula (II).

[0101] The reaction is in general carried out in a tempera e range from 0° C. to 150° C., preferably from +20° C. to +110° C.

[0102] The reaction can be carried out at normal, increased or reduced pressure (e.g. 0.5 to 5 bar). In general, the reaction is carried out at normal pressure.

[0103] The amidation can optionally proceed via the activated stage of the acid halides, Ahich can be prepared from the corresponding acids by reaction with thionyl chloride, phosphorus trichloride. phosphorus pentachloride, phosphorus tribromide or oxalyl chloride.

[0104] The abovementioned bases can optionally also be employed for the amidation as acid-binding auxiliaries.

[0105] Suitable auxiliaries are also dehydrating reagents. These include, for exarnple, carbodjimides such as diisopropylcarbodiimide, dicyclohexylcarbodiimide and N-(3-dimethylaminopropy l)N′-ethylcarbodiimide hydrochloride or carbonyl compounds such as carbonyldiidazole or 1,2-oxazoliumn compounds such as 2-ethyl-5-phenyl-1 ,2-oxazolium-3-sulphonate or propanephosphonic anhydride or isobutyl chloroformate or benzotriazolyloxy-trisdimethylaniino)phosphonium hexafluorophosphate or diphenyl phosphoramidate or metlianesulphonyl chloride, if appropriate in the presence of bases such as triethylamine or N-ethylmorpholine or N-methylpiperidine or dicyclohexylcarbodiimide and N-hydroxysuccinimide.

[0106] The acid-binding agents and dehydrating reagents are in general employed in an amount from 0.5 to 3 mol, preferably from 1 to 1.5 mol, relative to 1 mol of the corresponding carboxylic acids.

[0107] The variation of functional groups, for example hydrolysis, esterification and reduction, and also separation of isomers and salt formation is carried out by customary methods.

[0108] The carboxylic acids of the general formula (II) are new and can be prepared by reacting compounds of the general formula 8

[0109] in which

[0110] D has the meaning indicated,

[0111] T represents a typical leaving group, for example chlorine, bromine, iodine, tosylate or mesylate, preferably bromine,

[0112] and

[0113] R18 represents (C1-C4)-alkyl, with compounds of the general formula (V) 9

[0114] in which

[0115] R1, R2, R3 and R4 have the meaning indicated, in inert solvents, if appropriate in the presence of a base.

[0116] Suitable solvents for the process are the customary organic solvents which do change under the reaction conditions. These preferably include ethers such as diethyl ether, dioxane, tetrahydrofiwan, glycol dimethyl ether, or hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, or halogenohydrocarbons such as dichloromethane, trichioromethane, tetrachioromethane, dichioroethylene, trichloroethylene or chloroleezene, or ethyl acetate, triethylamine, pyridine, dimethyl sulphoxide, dimethylformamide, hexarnethylphosphoranide, acetonitrile, acetone or nitromethane. It is also possible to use mixtures of the solvents mentioned. Dimethylformamide and tetrahydrofuran are preferred.

[0117] The bases employed for the process according to the invention can in general be inorganic or organic bases. These preferably include alkali metal hydroxides, for example, sodium hydroxide or potassium hydroxide, alkaline earth metal hydroxides, for example, barium hydroxide, alkali metal carbonates such as sodium carbonate or potassium carbonate, alkaline earth metal carbonates such as calcium carbonate, or alkali metal alkoxides such as sodium or potassium methoxide, sodium or potassium ethoxide or potassium tert-butoxide, or organic arnines (trialkyl(C1-C6)arnines) such as triethylamine, or heterocycles such as 1,4diazabicyclo[2.2.2]octane (DABCO), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), pyridine, diamninopyridine, methylpiperidine or morpholine. It is also possible to employ alkali metals such as sodium or their hydrides such as sodium hydride as bases. Sodium hydride, potassium carbonate, triethylamine, pyridine and potassium tert-butoxide, DBU or DABCO are preferred.

[0118] In general, the base is employed in an amount from 0.05 mol to 10 mol, preferably from 1 mol to 2 mol, relative to 1 mol of the compound of the formula (IV).

[0119] The process according to the invention is in general carried out in a te pee range from −30° C. to +100° C., preferably from −10° C. to +60° C.

[0120] The process according to the invention is in general carried out at normal pressure. However, it is also possible to carry out the process at elevated pressure or at reduced pressure (e.g. in a range from 0.5 to 5 bar).

[0121] The compounds of the general formula (III) are known per se.

[0122] The compounds of the general formula (IV) are known or can be prepared in analogy to known methods.

[0123] The compounds of the general formula (V) are known or can be prepared in analogy to known methods.

[0124] The compounds of the general formula (I) according to the invention have an unforeseeable spectrum of pharmacological action.

[0125] They can be used as active compounds in medicaments for the reduction of changes to vessel walls and for the treatment of coronary heart disorders, cardiac insufficiency, brain power disorders, ischaernic brain disorders, apoplexy, circulatory disorders, disorders of the microcirculation and thromboses.

[0126] Furthermore, the proliferation of smooth muscle cells plays a decisive part in the occlusion of vessels. The compounds according to the invention are suitable for inhibiting this proliferation and thus preventing atherosclerotic processes.

[0127] The compounds according to the invention are distinguished by a lowering of the ApoB-100-associated lipoproteins (VLDL and its degradation products, e.g. LDL), of ApoB-100, of triglycerides and of cholesterol. They thus have useful, superior pharmacological properties in comparison with the prior art.

[0128] Surprisingly, the action of the compounds according to the invention consists first in a decrease or complete inhibition of the formation and/or the release of ApoB-100-associated lipoproteins from liver cells, which results in a lowering of the VLDL plasma level. This lowering of VLDL must be accompanied by a lowering of the plasma level of ApoB100, LDL, triglycerides and cholesterol; a number of the abovementioned risk factors lhich are involved in vessel wall changes are thus simultaneously decreased.

[0129] The compounds according to the invention can therefore be employed for the prevention and treatment of atherosclerosis, obesity, pancreatitis and constipation.

[0130] I Inhibition of Die Lease of ApoB-100 Associated Lipopnteins

[0131] The test for detecting the inhibition of the release of ApoB-100-associated lipoproteins from liver cells was carried out in vitro using cultured liver cells, preferably using cells of the human line HepG2. These cells are cultured under standard conditions in medium for the culture of eukaryotic cells, preferably in RPMI 1640 With 10% foetal calf serum. HepG2 cells synthesize and secrete into the culture supernatant ApoB-100-associated lipoprotein particles which in principle are built up in a similar manner to the VLDL and LDL particles which are to be found in the plasma

[0132] These particles can be detected using an immunoassay for human LDL. This immunoassay is carried out using antibodies which have been induced against human LDL in rabbits under standard conditions. The anti-LDL antibodies (rabbit anti-LDL Ab) wevere purified by affiity chromatography on an inununosorbent using human LDL. These purified rabbit anti-LDL Ab are adsorbed on the surface of plastic. Expediently, this adsorption is carried out on the plastic surface of microtitre plates having 96 wells, preferably on MxiSorp plates. If ApoB-100-associated particles are present in the supernatant of HeG2 cells, they can be bound to the insolubilized rabbit anti-LDL Ab, and an immune complex results which is bound to the plastic surface. Unbound proteins are removed by washing. The immune complex located on the plastic surface is detected using monoclonal antibodies whch have been induced against human LDL and purified according to standard conditions. These antibodies were conjugated with the enzyme peroxidase. Peroxidase converts the colourless substrate TUB into a coloured product in the presence of H2O2. After acidification of the reaction mnute with H2SO4, the specific light absorption at 450 nm is detemined, vhich is a measure of the amount of ApoB-100associated particles which have been secreted into the culture supernatant by the HepG2 cells.

[0133] Surprisingly, the compounds according to the invention inhibit the release of the ApoR100-associated particles. The IC50 value indicates at which substance concentration the light absorption is inhibited by 50% in comparison with the control (solvent control without substance).

Ex. No. IC50 [10−9 mol/l]
1       28
5       1.1
31      170
50      29

[0134] 2. Determination of the VLDL Secretion in vivo in the Hamster

[0135] The effect of the test substances on VLDL secretion in vivo is investigated in the hamster. To do this, golden hamsters are anaesthetized with Ketaset (83 mg/kg s.c.) and Nembutal (50 mg/kg i.p.) after premedication with atropine (83 mg/kg s.c.). When the animals have become reflex-free, the jugular vein is exposed and cannulated. 0.25 ml/kg of a 20% strength solution of Triton WR-1339 in physiological saline solution is then administered. This detergent inhibits the lipoprotein lipase and thus leads to a rise in the triglyceride level as a result of a lack of catabolism of secreted VLDL particles. This triglyceride rise can be used as a measure of the VLDL secretion rate.

[0136] Blood is taken from the animals before and also one and two hours after administration of the detergent by puncture of the retroorbital venous plexus. The blood is incubated for two hours at room te ue, and then overnight at 4° C., in order to end clotting completely. It is then centrifuged at 10,000 g for 5 minutes. The triglyceride concentration in the serum thus obtained is determined with the aid of a modified commercially available enzyme test (Merckotest® triglyceride No. 14354). 100 μl of serum are treated with 100 μl of test reagent in 9Ohole plates and incubated at room temperature for 10 ninutes. The optical density is then determined at a wavelength of 492 nM in an automatic plate-reading apparatus (SLT Spectra). Serum samples having an excessively high triglyceride concentration are diluted with physiological saline solution. The triglyceride concentration contained in the samples is determined with the aid of a standard curve measured in parallel. In this model, test substances are administered intravenously either immediately before administration of the detergent or orally or subcutaneously before initiation of anaesthesia.

Ex. No. ED50 [mg/kg] p.o.
2       10-15
5       3-6
1       10-20

[0137] 3. Inhibition of Intestinal Triglyceride Absorption in vivo (Rats)

[0138] The substances which are to be investigated for their triglyceride absorption-inhibiting action in vivo are administered orally to male Wistar rats having a body weight of between 170 and 230 g. For this purpose, the animals are divided into groups of 6 animals 18 hours before substance administration and food is then withdrawn from them. Drking water is available to the animals ad libitum The animals of the control groups receive an aqueous tragacanth suspension or a tragacanth suspension which contains olive oil. The tragacanth-olive oil suspension is prepared using an Ultra-Turrax. The substances to be investigated are suspended in an appropriate tragacanth-olive oil suspension likewise using the Ultra-Turrax, directly before substance administration.

[0139] To determine the basal sem triglyceride content, blood is taken from each rat by puncture of the retroorbital venous plexus before stomach tube application The tragacanth suspension, the tragacanth-olive oil suspensions without substance (control arimals) or the substances suspended in an appropriate tragacanth-olive oil suspension are then administered to the fasting animals using a stomach tube. Further taking of blood to determine the postprandial serum triglyceride rise is carried out, as a rule, 1, 2 and 3 hours after stomach tube application.

[0140] The blood samples are centrifuged and, after recovering the serum, the triglycerides are determined photometrically using an EPOS analyzer 5060 (Eppendorf Geratebau, Netheler & Hinz GmbH, Hamburg). The determination of the triglycerides is carried out completely enz)matically using a standard cornnercial UV test.

[0141] The postprandial serum triglyceride rise is determined by subtraction of the triglyceride preliminary value of each animals from its corresponding postprandial triglyceride concentrations (1, 2 and 3 hours after adrninistration).

[0142] The differences (in mmouL/) at each point in time (1, 2 and 3 hours) are averaged in the groups, and the mean values of the serum triglyceride rise (Δ TG) of the substance-treated animals is compared with the animals which only received the tragacanth-oil suspension.

[0143] The serum triglyceride course of the control animals which only received tragacanth is also calculated The substance effect at each point in time (1, 2 and 3 hours) is determined as follows and indicated in Δ% of the oil-loaded control. 1$\Delta \%\mathrm{Triglyceride}\mathrm{rise}=\frac{\Delta {\mathrm{TG}}_{\mathrm{substance}}-\Delta {\mathrm{TG}}_{\mathrm{tragacanth}\mathrm{control}}}{\Delta {\mathrm{TG}}_{\mathrm{oil}\mathrm{loading}}-\Delta {\mathrm{TG}}_{\mathrm{tragacanth}\mathrm{control}}}\times 100$

[0144] Effect of 10 mg of test substance/kg of body weight p.o. on the triglyceride rise (Δ%) 2 h after a triglyceride loading in the serum of fasting rats. Tlhe serum triglyceride nrse of fat-loaded control animals relative to the serum triglyceride level of tragacanth control anims corresponds to 100%. n=6 amus per group.

                     Serum triglyceride use in % (2 h
                     pp)
Triglyceride loading 100
Tragacanth control   0
Substance 10 mg/kg of body weight p.o.
Ex. No. 10           34
Ex. No. 66           67
Ex. No. 54           54
Ex. No. 71           18
Ex. No. 5            −16
Ex. No. 20           35

[0145] Statistical evaluation is carried out using Student's t test after preliminary checking of the variances for homogeneity.

[0146] Substances which at one point in time statistically significantly (p<0.05) decrease the postprandial senun triglyceride rise by at least 30% compared with the untreated control group are regarded as pharmacologically active.

[0147] 4. Inhibition of VLDL Secrtion in vivo (Rats)

[0148] The action of the test substances on VLDL secretion is likewise investigated in the rat. To do this, 500 mg/kg of body weight (2.5 mgkg) of Triton WR-1339, dissolved in physiological saline solution, is administered intravenously into the tail vein of rats. Triton WR-1339 ihibits lipoprotein lipase and thus leads to an increase in the triglyceride and cholesterol level by inhibition of the VLDL catabolism. These rises can be used as a measure of the VLDL secretion rate.

[0149] Blood is taken from the animals by puncture of the retroorbital venous plexus before and also one and twvo hours after administration of the detergent. The blood is incubated at room temr ure for 1 h for clotting and the serum is obtained by centrifugation at 10,000 g for 20 s. The triglycerides are then photometrically determined by means of a standard commercial coupled enzyme test (Sigma Diagnostics®, No. 339) at a wavelength of 540 nrm Measurement is carried out with the aid of a likewise coupled enzyme test (Boehring Mannheim®, No. 1442350) at a wavelength of 546 nm. Samples with triglyceride or cholesterol concentrations which exceed the measuring range of the methods are diluted with physiological saline solution. The determination of the respective serum concentrations is carried out with the aid of standard series measured in parallel. Test substances are administered orally, intravenously or subcutaneously immediately after the Triton injection.

[0150] The invention additionally relates to the combination of cycloalkano-indole and -azaindole derivatives of the general formula (1) with glucosidase and/or amylase ihibitor for the treatment of familial hyperlipidaemia, obesity (adiposity) and diabetes mellitus. Glucosidase and/or arnylase inhibitors in the context of the invention are, for example, acarbose, adiposine, voglibase, miglitol, emiglitate, MDL 25637, camialibase (MDL 73945), tendamnistat, AI-3688, trestatin, pradimnilin-Q and salbostatin.

[0151] Combination of acarbose, miglitol, emiglitate or voglibase with one of the abovementioned compounds of the general formula (I) according to the invention is preferred.

[0152] The new active compounds can be converted in a known manner into the customary formulations, such as tablets, coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, non-toxic, pharmaceutically suitable excipients or solvents. In this case, the therapeutically active compound should in each case be present in a concentration of approximately 0.5 to 90% by weight of the total mixture, i.e. in amounts which are sufficient in order to achieve the dosage range indicated.

[0153] The formulations are prepared, for example, by extending the active compounds with solvents and/or excipients, if appropriate using emulsifiers and/or dispersants, it optionally being possible, e.g. in the case of the use of water as a diluent, to use organic solvents as auxiliary solvents.

[0154] Administration is carried out in a customary manner, preferably orally or parenterally, in particular perlingually or intravenously.

[0155] In the case of parenteral administration, solutions of the active compound can be employed using suitable liquid vehicles.

[0156] In general, it has proved advantageous in the case of intravenous adminstration to administer amounts of approxinately 0.001 to 1 mg/k of body weight, preferably approxijmaely 0.01 to 0.5 mgtkg of body weight, to achieve effective results. and in the case of oral adrministration the dose is approximately 0.01 to 20 mg/kg of body weight, preferably 0.1 to 10 mg/kg of body weight.

[0157] In spite of this, it may optionally be necessary to depart from the amounts mentioned, namely depending on the body weight or on the type of administration route, on individual behaviour towards the medicament, the manner of its formulation and the time or interval at which administration takes place. Thus, in some cases it may be adequate to manage with less than the abovementioned minimum amount. while in other cases the upper limit mentioned must be exceeded. In the case of the administration of larger amounts, it may be advisable to divide these into several individual doses over the course of the day.

[0158] Definition of the Isomer Types:

[0159] 4 dia=mixture of the four possible diastereomers in the case of two centres of asymmetry in the molecule

[0160] dia A=diastereomer having the larger Rf value

[0161] dia B=diastereomer having the smaller Rf value

[0162] ent=enantiomer

[0163] 2 ent dia=mixture of two enantiomerically pure diastereomers

[0164] ent dia A=enantiomerically pure diastereomer having the larger Rf value

[0165] ent dia B=enantiomerically pure diastereomer having the smaller Rf value

[0166] R=R enantiomer

[0167] rac=racernate

[0168] rac dia A=racemic diastereomer having the larger Rf value

[0169] rac dia B=racermic diastereomer having the smaller Rf value

[0170] S=S enantiomer

[0171] Abbevations Used:

[0172] Ac=acetyl

[0173] Bn=benzyl

[0174] Bz=benzoyl

[0175] iB=isobutyl

[0176] nBu=normnal butyl

[0177] sBu=secondary butyl

[0178] tBu=tertiary butyl

[0179] DDQ=2,3-dichloro-5,6dicyano-1,4benzoquinone

[0180] cDec=cyclodecyl

[0181] DMF=N,N-dimethylformamide

[0182] DMSO=dimethyl sulphoxide

[0183] cDodec=cyclododecyl

[0184] Et=ethyl

[0185] cHept=cycloheptyl

[0186] cHex=cyclo-hexyl

[0187] HOBT=1-hydroxy-1H-benzotriazole

[0188] Me=metlyl

[0189] Mes=mesyl

[0190] cNon=cyclo-nonyl

[0191] cOct=cyclo-octyl

[0192] cPent=cyclo-pentyl

[0193] nPent=normal pentyl

[0194] Ph=phenyl

[0195] cPr=cyclo-propyl

[0196] nPr=normal propyl

[0197] iPr=isopropyl

[0198] THF=tetrahydrofiirn

[0199] TMS=tetramethylsilane

[0200] pTol=para-tolyl

[0201] pTos=para-tosyl

[0202] cUndec=cyclo-undecyl

[0203] Solvent Symbol

[0204] Dichloromethane: methanol=20:1 A

[0205] Dichloromehane: methanol=50:1 B

[0206] Dichloromethane: ethanol=20:1 C

[0207] Dichiorometiane: ethanol=50:1 D

[0208] Petroleum ether: ethyl acetate=1:1 E

[0209] Dichloromethane: methanol: acetic acid=90:10:2 F

[0210] Petroleum ether: ethyl acetate=2:1 G

[0211] Petroleum ether: ethyl acetate=10: 1 H

[0212] Toluene I

[0213] Toluene: ethyl acetate=1:1 K

[0214] Petroleum ether: ethyl acetate=5:1 L

[0215] Dichloromethane M

[0216] Petroleum ether: ethyl acetate=20:1 N

[0217] Dichloromethane: methanol 10:1 0

[0218] Cyclohexane: ethyl acetate=1: 1 p

[0219] Toluene: ethyl acetate=9:1 Q

[0220] Toluene: ethyl acetate=8:1 R

[0221] Petroleum ether: ethyl acetate=1:2 S

[0222] Dichloromethane: ethanol=5:1 T

[0223] Dichloromethane: ethanol=10:1 U

[0224] Preparion Procedure for the TLC Mobile Phase BABA:

[0225] 87.9 ml of an aqueous 0.06667 molar potassium dihydrogen phosphate solution and 12.1 ml of an aqueous 0.06667 molar disodium hydrogen phosphate solution are mixed 60 ml of the solution prepared in this way are shaken with 200 ml of n-butyl acetate, 36 ml of n-butarol and 100 ml of glacial acetic acid and the aqueous phase is removed The organic phase is the mobile phase BABA.

Starting Compomds

EXAMPLE I

[0226] 1 -Allyloxy-2-chloromethylbenzene 10

[0227] 11.5 g (70 mmol) of 1-allyloxy-2-hydroxymethyl-benzene are treated with 11.6 ml (84 mrnol) of triethylamine at 0° C. in 110 ml of dichloromethane and then slowly reacted with 5.4 ml (70 mmol) of methanesulphonyl chloride. After 4 hours, the mixture is extracted several times with water, and the organic phase is dried over magnesium sulphate and evaporated. Residual solvent is removed in a high vacuum

[0228] Yield: 8.5 g

[0229] Rf=0.23 (dichloromethane: ethanol 20: 1)

EXAMPLE II

[0230] (2-Allyloxy-benzyl)amine 11

[0231] 3 0 g (16.4 mmol) of the compound from Example I are boiled under reflux for 17 hours in 250 ml of a saturated methanolic ammonia solution. The reaction mixture is evaporated in vacuo, the residue is taken up in methanol and the nii)ue is evaporated again; this process is repeated a few times. The crude product is taken up in dichioromethane and extracted several times with water. The aqueous phase is evaporated to a vey great extent, an oil being obtained which crystallizes on standing.

[0232] Yield: 0.454 g (crude)

[0233] The product is reacted furter without ftirter purification.

[0234] Rf=0.41 (mobile phase: BABA)

EXAMPLE III

[0235] 6-Chloro-2,4lutidine 12

[0236] For the preparation of the title compound [US 36 32 807], 600 g (4.91 mol) of 6-amino-2,41utidine are dissolved in 2 1 of methanol and the solution is saturated with hydrogen chloride gas at about 0° C. 1.3071 (9.82 mol) of isopentyl nitrite are added dropwise (about 2.5 h) at an internal temperate of below 10° C. and the mixture is left in this way for 15 h ,hile warming to room temperature (about 25° C.). The solution is largely freed from the solvent in vacuo, mixed with 3 l of dichloromethane and 1.5 l of water and adjusted to pH=9.5 awhle cooling (<20° C.) with concentrated aqueous ammonia solution. The separated organic phase is dried with sodium sulphate, first concentrated in vacuo on a rotary evaporator and then distilled through a Vigreux column:

[0237] Fraction 1) B.p.=47-49° C. (12 mm Hg), 603 g

[0238] Fraction 2) B.p.=82-85° C. (12 mm Hg), 612 g (about 88% crude)

[0239] Rf=0.39 (petroleum ether: ethyl acetate=10:1)

[0240] 1 H-NMR (CDCl3 200 MHz, TMS): δ=2.28 (S, 3 H), 2.47 (S, 3 H), 6.88 (S, 1 H), 6.96 (S, 1 H) ppm.

[0241] The crude product, which may contain small amounts of 6methoxy-2,4lutidine, is reacted flirther without frther purification. Exe IV 6-Hydrazino-2,4-lutidine (4,6-dimethyl-2-hydrazino-pyridine) 13

[0242] 580 g (4.10 mol) of the compound from Example III are dissolved in 800 ml of diethylene glycol and the solution is stirred with 1050 ml of hydrazine hydrate for 48 h at a bath temperature of about 140° C. The cooled mixture is poured into 4.5 l of ether and 4.5 l of water and the organic phase is extracted twice with 2.3 l of dichloromethane each time. The combined organic phases are dried with sodium sulphate and evaporated in vacuo. 784 g of solventwntaining crude product are obtained, Which is reacted further without working up.

[0243] Rf=0.37 (dichloromethane: methanol=10:1)

[0244] 1 H-NMR (d6—DMSO, 250 MHz, TMS): δ=2.13 (S, 3 H), 2.22 (S, 3 H), 4.02 (S, 2 H), 6.26 (S, 1 H), 6.35 (S, 1 H), 7.11 (S, 1 H) ppm.

Example V

[0245] 2-Hydrazino4-picoline (2-hydrazino-4-methylpyridine) 14

[0246] In analogy to the procedure of Example IV, 2-hydrazino-4-picoline is prepared from 2-chloro4-picoline.

[0247] Rf=0.06 (dicworomethane: methanol=10:1)

Example VI 2,4Dimethyl-5,6,7,8-tetrahydro-α-acroline

[0248] 15

[0249] 78 g (at most 0.49 mol) of crude compound from Example IV are reacted with 59 ml (0.56 mol) of cyclohexanone at room temperature (about 25° C.), whereon the internal tenure rises. After 2 h, the starting material has disappaed (TLC checking, dichloromethane: methanol=10:1). The mixture is taken up in 40 ml of diethylene glycol and reacted under reflux, constituents having a boiling point lower than the solvent (e.g. water of reaction and excess cyclohexanone) being removed by distillation (water separator). After 3 h, the intermediate hydrazone has disappeared (TLC checking, petroleum ether: ethyl acetate=1:1); the reaction mitue is cooled to room temperature and stirred with acetone. The precipitate obtained is filtered off with suction, washed with acetone and dried in vacuo (34.4 g). The largely solvent-free mother liquors are again treated with acetone, a fiber 9.3 g of product being obtained (total yield over three stages: 43.7 g/0.22 moI!47%).

[0250] M.p.: 248° C. (uncorrected)

[0251] Rf=0.41 (dichloromethane: methanol=20:1)

[0252] 1 H-NMR (d6-DMSO, 200 MHz, TMS): δ=1.78 (M, 4 H), 2.40 (S, 3 H), 2.48 (S, 3 H ), 2.64 (M, 2 H), 2.82 (M, 2 H), 6.57 (S, 1 H), 10.84 (S, 1 H) ppm.

[0253] The compounds of Table I are prepared analogously to the procedure of Example VI.

TABLE I
			Starting material
Ex. No.		Rf (solvent)	(hydrazine*)
VII	16	0.59 (A)	Ex. No. IV
VIII	17	0.36 (E)	Ex. No. IV
IX	18	0.45 (G)
X	19	0.46 (E)
XI	20	0.06 (L)
XII	21	0.41 (E)
XIII	22	0.40 (E)
XIV	23	0.59 (O)
XV	24	0.34 (E)
XVI	25	0.42 (E)
XVII	26	0.59 (G)
XVIII	27	0.85 (G)

Example XIX

[0254] 2,4Dimethyl-α-carboline 28

[0255] 100 g (499 mmol) of the compound from Example VI are reacted under reflux with 164 ml (1 mol) of diethyl fumarate on 52 g of palladium (5% on carbon) in 700 ml of diethylene glycol. A small amount of ethanol distils off at the high internal temperature (if desired use a water separator). After about 8 h ,the starting material has disappeared (TLC checking, petroleum ether: ethyl acetate 1:1, detection in an iodine chamber). The cooled mixure is treated with 3 l of acetone, boiled, filtered off hot with suction through a clarifying filter (Seitz) and washed with 1 l of hot acetone. On cooling a precipitate is obtained NNhch yields 58.3 g of product after filtering Fith suction, rinsing with cold acetone and drying in vacuo. The mother liquor is largely freed from acetone in vacuo, the precipitate ich is deposited being worked up as above (9.4 g). The filtrate is again freed from acetone; after addition of n-pentane, product precipitates a fher time (3.1 g/working up see above); total yield 72%.

[0256] M p. 220-221° C. (uncorrected)

[0257] Rf=0.47 (petroleum ether: ethyl acetate=1:1)

[0258] 1 H-NMR (d6-DMSO, 200 MHz, TMS): 6=2.54 (S, 3 H), 2.75 (S, 3 H), 6.89 (S, 1 H), 7.20 (M, 1 H), 7.40 (M, 1 H), 7.48 (DD, 1 H), 8.05 (DD, 1 H), 11.61 (S, 1 H) ppm.

EXAMPLE XX

[0259] tert-Butyl 4methylphenyl-acetate 29

[0260] 450 g (3 mol) of 4-methylphenyl-acetic acid (Aldrich), 1.13 l (12 mol) of tert-butanol and 90 g (0.74 mol) of 4+,Ndiethylamino)pyridine are dissolved in 2 l of dichioromethane. After addition of 680 g (3.3 mol of dicyclohexylcarbodiimide, dissolved in 400 ml of dichloromethane, the mixture is stirred at 25° C. for 20 h, the precipitated urea is filtered off with suction and washed with 200 ml of dichloromethane, and the organic phase is washed twice each ith 500 ml of 2 M hydrochloric acid and water. The organic phase is concentrated and distilled.

[0261] Yield: 408 g (66% of theory)

[0262] Boiling point: 73-78° C./0.2 mm

Example XXI

[0263] tert-Butyl 2-Cyclopentyl-2-(4methlphenyl)acetate 30

[0264] 33.5 g (0.3 mol of potassium tert-butoxide are initially introduced into 100 ml of anhydrous DMF at 0° C., and 51.6 g (0.25 mol) of the compound from Bxample XX in 250 nml of anhydrous DMF are added dropwise. The mixture is stirred at 0C for 30 min and 32.2 ml (0.3 mol) of cyclopentyl bromide in 150 ml of anhydrous DMF are added dropwise at 5-15° C. and the mixture is stirred at 25° C. for 20 h. After concentrating, the residue is partitioned between water and diethyl ether, and the ether phase is dried over sodium sulphate and concentrated. The product crystallizes out.

[0265] Yield: 67 g (97.5% of theory)

[0266] Solidification point: 51-53° C.

[0267] The compounds of Table II are prepared in analogy to the procedure of Example XXI:

TABLE II
31
Ex. No.	D	R19	Rf (solvent)	Starting materia*
XXII	cHex	tBu	0.71 (I)	Ex. No. XX
XXIII	cHept	tBu	0.32 (I)	Ex. No. XX
XXIV	iPr	CH3	0.86 (Q)	sigma
XXV	iBu	tBu	0.84 (R)	Ex. No. XX
XXVI	cPent	CH3	0.59 (H)	sigma
XXVII	cHept	CH3	0.57 (I)	sigma

Example XXVIII

[0268] tert-Butyl 2-(4-bromomethy1-phenyl)2-cyclopentyl-acetate 32

[0269] 27.4 g (0.1 mol) of the compound from Example XXI are dissolved in 200 ml of tetrachloromedmane and the solution is heated to boiling. After addition of 0.82 g of azobisisobutyronitrile, 18.7 g (0.105 mol) of N-bromosuccilimide are added in portions and the mixture is then refluxed for 1 h, cooled to 0° C. and succinimide is filtered off. After concentrating the filte the product precipitates. It is washed with petroleum ether (40/60) and dried.

[0270] Yield: 20 g (57% of theory)

[0271] Nip.: 73-76° C.

[0272] The compounds of Table Im are prepared analogously to the procedure of Example XXVIII:

TABLE III
33
				Starting material*
Ex. No.	D	R19	Rf (solvent)	(Syn. from Ex. No.)
XXIX	cHex	tBu	0.58 (H)	Ex. No. XXII
XXX	cHept	tBu	0.84 (M)	Ex. No. XXIII
XXXI	iPr	CH3	0.78 (M)	Ex. No. XXIV
XXXII	iBu	tBu	0.86 (M)	Ex. No. XXV
XXXIII	cPent	CH3	0.63 (H)	Ex. No. XXVI
XXXIV	cHept	CH3	0.59 (I)	Ex. No. XXVII

EXAMPLE XXXV

[0273] tert-Butyl 2(RS)2-cclopentyl-2-[4 (2,4dimethyl-a-carbolin-9-yl)methyl]phenyl-acetate 34

[0274] 73.6 g(375 nuimol) of the compound from Example XIX are reacted at 25° C. for 30 min with 42.13 g (375 mmol) of potassium tert-butoxide in 700 nd of anhydrous N,N-dimethylfornande and the mixture is then treated xwith 161.7 g (375 mmol) of the compound from Example XXVIII, dissolved in 680 nd of anhydrous N,N-dimnethylforrarde. The reaction is complete after 1 h (TLC checking, petroleum ether : ethyl acetate=1 0: 1). For working up, 2 l of buffer solution (pH =4/Merck) and 2 l of water are added, the precipitate which is deposited is filtered off, washed with water and again filtered off rapidly. The moderately dam~p solid is then stirred succesively wvith petroleum ether and methanol and filtered off with suction. Vacuum drig over phosphorus pentoxide yields 139.8 g (298 mmot/79%) of product.

[0275] M.p.:160-161° C. (uncorrected).

[0276] is Rf=0.39 (petroleum ether : ethyl acetate=10:1)

[0277] 1 H-NMR (CDCl3, 250 Mhz TMVS): δ=0.91 (M 1 H), 1.18-1.68 M 6 H), 1.87 M 1 H), 1.47 (S, 9 H), 2.42 (M 1 H),2.66 (S, 3 H), 2.83 (S, 3 H) 3.09 (D, 1 H), 5.67 (S, 2 H), 6.88 (S, 1 H), 7.13-7.41 (M 7 H), 8.09 (D, 1 H), 111) ppm.

[0278] The compounds of Tables IV and V are prepared analogously to the procedure of Example XXXV:

TABLE IV
35
			Rf	Starting material
Ex. No.	Z	D	(solvent)	(Syn. from Ex. No.)
XXXVI	36	cPent	0.28 (H)	Benzyl bromide: Ex. No. XXVII Heterocycle: Ex. No. VI
XXXVII	37	cHept	0.47 (H)	Benzyl bromide: Ex. No. XXX Heterocycle: Ex. No. XIX
XXVIII	38	cHept	0.54 (L)	Benzyl bromide: Ex. No. XXX Heterocycle: Ex. No. VII
XXXIX	39	cHept	0.27 (H)	Benzyl bromide: Ex. No. XXX Heterocycle: Ex. No. VI
XL	40	cPent	0.59 (D)	Benzyl bromide: Ex. No. XXVIII Heterocycle: Ex. No. VIII
XLI	41	cHept	0.29 (H)	Benzyl bromide: Ex. No. XXX Heterocycle: Ex. No. VIII
XLII	42	cPent	0.70 (M)	Benzyl bromide: Ex. No. XXVIII Heterocycle: Ex. No. IX
XLIII	43	cHept	0.36 (H)	Benzyl bromide: Ex. No. XXX Heterocycle: Ex. No. IX
XLIV	44	cHept	0.48 (L)	Benzyl bromide: Ex. No. XXX
XLV	45	cPent	0.49 (C)	Benzyl bromide: Ex. No. XXVIII
XLVI	46	cPent	0.51 (C)	Benzyl bromide: Ex. No. XXVIII
XLVII	47	cPent	0.54 (C)	Benzyl bromide: Ex. No. XXVIII
XLVIII	48	cPent	0.37 (N)	Benzyl bromide: Ex. No. XXVIII Heterocycle: Ex. No. XI
IL	49	cHept	0.56 (H)	Benzyl bromide: Ex. No. XXX Heterocucle: Ex. No. XI
L	50	cPent	0.57 (C)	Benzyl bromide: Ex. No. XXVIII
LI	51	cHex	0.35 (H)	Benzyl bromide: Ex. No. XXIX Heterocycle: Ex. No. VI
LII	52	cHex	0.57 (B)	Benzyl bromide: Ex. No. XXIX Heterocycle: Ex. No. XIX
LIII	53	cPent	M.p. =189-190°C.	Benzyl bromide: Ex. No. XXVIII Heterocycle: a) C. Herdeis et al., Heterocycles 22, 2277 (1984).
LIV	54	iBu	0.49 (M) M.p.: 142° C. MS (Cl/NH3) 457 (100%)	Benzyl bromide: c) Ex. No. XXXII Heterocycle: c) Ex. No. XIX

[0279]

TABLE V
55
			Rf
			(solvent)	Starting material
Ex. No.	Z	D	MS/M.p.	(Syn. from Ex. No.)
LV	56	iPr	0.39 (M) M.p. = 159° C. MS (Cl/NH3): 401 (100%)	Benzyl bromide: Ex. No. XXXI Heterocycle: Ex. No. XIX
LVI	57	cPent	0.76 (B)	Benzyl bromide: Ex. No. XXXIII Heterocycle: Ex. No. XIX
LVII	58	cHept	0.26 (H)	Benzyl bromide: Ex. No. XXXIV Heterocycle: Ex. No. VI
LVIII	59	cHept	0.64 (K)	Benzyl bromide: Ex. No. XXXIV
LIX	60	cHept	0.29 (H)	Benzyl bromide: Ex. No. XXXIV Heterocycle: Ex. No. X
LX	61	cHept	0.30 (H)	Benzyl bromide: Ex. No. XXXIV Heterocycle: Ex. No. XIX

EXAMPLE LXI

[0280] 2-(R,S)-2-Cyclopentyl-2-[4-(2,4dimethyl-α-carbolin-9-yl)methyl]phenyl-acetic acid hydrochloride 62

[0281] 13 9.8 g, (298 mmol) of the compound from Example XXXV are dissolved in 1 l of 1,4doxane and the solution is stirred at 70° C. for 3 h with 240 ml of concentrated hydrochloric acid (37% strength). After reaction is complete (TLC checking, petroleum ether: ethyl acetate=10:1), the mxue is cooled to about 15° C. and then poured in portions into 5 l of water. The pH is adjusted to 2.8 using 2 M aqueous sodium hydroxide solution, and the precipitate obtained is filtere off with suction through a paper filter and washed with water until the washing water has a pH>4. The rapidly filtered off solid is stirred with I I of petroleum ether (boilig range 60-80° C.), filtered off with suction again and dried over phosphorus pentoxide in vacuo.

[0282] Yield: 130.3 g (290 mmol/97%/)

[0283] M.p.: 260-262° C. (uncorrected)

[0284] Rf=0.51 (dichlorometliane : ethanol=20: 1)

[0285] 1 H-NM (d6-DMSO, 200 MHz, TMS): δ=0.88 (M 1 H), 1.09-1.67 (M, 6 H) 1.79 (M, 1 H), 2.38 (M, 1 H), 2.68 (S, 3 H), 2.84 (S, 3 H), 3.16 (D, 1 H), 4.7-5.9 (1 H), 5.80 (S, 2 H), 7.12-7.26 (M, 5 H), 7.32 (M, 1 H), 7.49 (M, 1 H), 7.59 (D, 1 H), 8.17 (D, 1 H) ppm The compounds of Table VI are prepared analogously to the procedure of Example LXI:

TABLE VI
63
			Rf	Starting material
Ex. No.	Z	D	(solvent)	(Syn. from Ex. No.)
LXII	64	cPent	0.37 (A)	Ex. No. XXXVI
LXIII	65	cHept	0.23 (G)	Ex. No. XXXVII
LXIV	66	cHept	0.30 (E)	Ex. No. XXXVIII
LXV	67	cHept	0.27 (D)	Ex. No. XXXIX
LXVI	68	cPent	0.37 (C)	Ex. No. XL
LXVII	69	cHept	0.15 (C)	Ex. No. XLI
LXVIII	70	cPent	0.43 (A)	Ex. No. XLII
LXIX	71	cHept	0.27 (C)	Ex. No. XLIII
LXX	72	cHept	0.17 (E)	Ex. No. XLIV
LXXI	73	cPent	0.07 (C)	Ex. No. XLV
LXXII	74	cPent	0.26 (C)	Ex. No. XLVI
LXXIII	75	cPent	0.39 (C)	Ex. No. XLVII
LXXIV	76	cPent	0.46 (C)	Ex. No. XLVIII
LXXV	77	cHept	0.68 (E)	Ex. No. IL
LXXVI	78	cPent	0.44 (C)	Ex. No. L
LXXVII	79	cHex	0.44 (C)	Ex. No. LI
LXXVIII	80	cHex	0.55 (C)	Ex. No. LII
LXXIX	81	cPent	M.p. = 204-205° C.	Ex No. LIII
LXXX	82	iBu	0.36 (A) M.p.: 156° C. MS(FAB): 401 (100%) 154 (90%)	Ex. No. LIV

EXAMPLE LXXXI

[0286] 2-(R, S)-2-[4-(2-Methyl-5 ,6, 7, 8-tetrahydro-α-carbolin-9-yl)-methyl-phenyl]-2-cylcoheptyl-acetic acid 83

[0287] 1.5 g (3.37 mmol) of the compound from Example LIX are reacted with 20 ml of 1 M methanolic sodium hydroxide solution for 48 h. Water is added thereto and the methanol component is evaporated. The alkaine aqueous phase is extracted several times with ether, freed from residues of organc solvent in vacuo and adjusted to a pH of about 2 at 0-5° C. using aqueous 1 M hydrochloric acid. The precipitate which is deposited in this process is filtered off with suction, thoroughy washed with water and dried over phosphorus pentoxide in a high vacuum.

[0288]

[0289] Yield: 1.18 g

[0290] The reaction can be accelerated using potassium hydroxide instead of sodium hydroxide and with addition of 1. 4, 7, 10, 13, 16-hexaoxacyclooctadecane.

[0291] Rf=0.39 (ptoleum ether : ethyl acetae=2:1)

[0292] The compounds of Table VII are prepared in analogy to the procedure of Example LXXXI:

TABLE VII
84
					Starting
				Rf	material
				(solvent)	(Synthesis
Ex. No.	Z	D	1	MS/M.p.	from Ex. No.)
LXXXII Method 1	85	iPr	rac	0.28 (A) M.p. = 225° C. MS(FAB): 387 (100%) 154 (80%)	Ex. No. LV
LXXXIII	86	cHept	rac	0.05 (L)	Ex. No. LVII
LXXXIV	87	cHept	rac	0.11 (K)	Ex. No. LVIII
LXXXVI	88	cHept	rac	0.23 (G)	Ex. No. LX
LXXXVI	89	cPent	rac	0.51 (C)	Ex. No. LVI

[0293] Example LXXXII can also be prepared by method 2 which follows:

[0294] 2-[4(2,4Dimethyl-α-carbolin-9-yl)-methyl-phenyl]-2-(prop-2-yl)acetic acid 90

[0295] 1.11 g (2.77 mmol) of the compound from Example No. LV are boiled under reflux for 18 hours in 45 ml of methanol and 3 ml of 2 M aqueous sodium hydroxide solution. As the reaction is incomplete according to TLC (dichloromethane: methanol═20: 1), 30 ml of tetrahydrofuran and a furither 3 ml of 2 M aqueous sodium hydroxide solution are added, a clear solution being obtained. After boiling under reflux for four hours, the reaction is complete (TLC, see above). The mixture is cooled, diluted with water and neutralized with 2 M aqueous hydrochloric acid. The precipitate which is obtained in this process is filtered off with suction, washed with water and dried over phosphorus pentoxide in vacuo.

[0296] Yield: 0.597 g

[0297] M.p.=225° C.

[0298] Rf=0.28 (dichloromethane: methanol=20:1)

[0299] The compounds of Table VIII are prepared analogously to the procedure of Example XXXV:

TABLE VIII
91
Ex. No.	—Z	M.p. (° C.)	Starting material*
LXXXVII	92	164-165
LXXXVIII	93	201-202
*Ex. No. XXVIII was employed as the benzylbromide.

[0300] The compounds of Table IX are prepared analogously to the procedure of Example LXI:

TABLE IX
94
			Starting material from
Ex. No.	—Z	M.p. (° C.)	Ex. No.
LXXXIX	95	262-263	LXXXVII
XC	96	279-280	LXXXVIII

EXAMPLE XCI

[0301] 2-Hydrazino-5-trifluoromethylpyridine 97

[0302] In analogy to the procedure of Example No. IV, 2-hydrazino-5-trifluoromethylpyrdine is prepared from 2-chloro-5-trifluoromethylpyridine.

[0303] Rf=0.37 (BABA)

EXAMPLE XCII

[0304] 5-Oxo-5,6,7-tetrahydro-α-carboline 98

[0305] 3.3 g (19.2 mmol) of 5,6,7,8-tetrahydro-α-carboline (Lit.: S. Okuda and M. M. Robinson, J. Am. Chem. Soc. 81, 740 (1959)) are initially introduced into 43 ml of tetrahydroran while stirring at 0° C. and the mixture is treated dropwise with a solution of 15.5 g (68.2 mmol) of DDQ in 277 ml of tetrahydrofirn and 31 ml of water. The reaction mixture is stirred at 0° C. for 5 minutes and at 20° C. for 2 hours, then treated with a buffer of pH=10 (Merck) and extracted with diethyl ether. The evaporated organic phase yields a crude product which is purified by chromatography (silica gel 60, Merck, first petroleum ether: ethyl acetate=1:1, then dichloromethane : methanol=20:1). The fractions thus obtained are precipitated by stirring with acetone, and the product is filtered off with suction and freed from the solvent in vacuo.

[0306] Yield: 0.92 g

[0307] Rf=0.17 (petroleum ether: ethyl acetate=1:4).

[0308] The compounds of Table X are prepared analogously to the procedure of Example VI:

TABLE X
		M.p. (° C.)		Starting material
Ex. No.	—Z—	Rf (solvent)	MS (EI)	from Ex. No.
XCIII	99	0.27 (E)		V
XCIV	100	0.46 (G)	240 (52%) 212 (100%)	XCI
The compounds of Table XI are prepared analogously to the procedure of Example XIX:

[0309]

TABLE XI
		M.p. (° C.)		Starting material
Ex. No.	—Z—	Rf (solvent)	MS (EI)	from Ex. No.
XCV	101	0.39 (G)	250 (100%)	IX
XCVI	102	0.45 (G)		X
XCVII	103	0.48 (G)	236 (100%)	XCIV
XCVIII	104	0.3 (E)		XCIII

[0310] The compounds of Table XII are prepared analogously to the procedure of Example Table XXXV:

TABLE XII
105
			M.p. [° C.]	Starting material
Ex. No.	Z	D	Rf (solvent)	from Ex. No.
IC	106	cPent	0.73 (C)	Benzyl bromide: Ex. No. XXVIII
C	107	cPent	0.63 (H)	Benzyl bromide: Ex. No. XXVIII Heterocycle: Ex. No. XCV
CI	108	cPent	0.27 (H)	Benzyl bromide: Ex. No. XXVIII Heterocycle: Ex. No. XCVI
CII	109	cPent	0.33 (H)	Benzyl bromide: Ex. No. XXVIII Heterocycle: Ex. No. XCI
CIII	110	cPent	0.41 (H)	Benzyl bromide: Ex. No. XXVIII Heterocycle: Ex. No. XCVII
CIV	111	cPent	0.18 (H)	Benzyl bromide: Ex. No. XXVIII Heterocycle: Ex. No. XCVIII

[0311] The compounds of Table XIII are prepared analogously to the procedure of Examnple LXI:

TABLE XIII
112
			M.p. [° C.]	Starting material
Ex. No.	Z	D	Rf (solvent)	from Ex. No.
CV	113	cPent	0.27 (C)	IC
CVI	114	cPent	0.49 (C)	C
CVII	115	cPent	0.38 (C)	CI
CVIII	116	cPent	0.35 (C)	CII
CIX	117	cPent	0.43 (C)	CIII
CX	118	cPent	0.29 (C)	CIV

EXAMPLE NO. CXI

[0312] 1-(RS)-1-Phenyl-2-triphenylmethyloxy-ethanol 119

[0313] 13 g (94 mmol) of 1(R,S)-1-Phenyl-2-hydroxy-ethanol are reacted at 20° C. with 15.6 ml (113 mmol) of trietiylamine and 23.6 g (84.6 mmol) of triphenylmethyl chloride in 200 ml of DNF. After 20 h,e mixture is poured into buffer of pH=4 (Merck), the phases are separated, and the organic phase is dried with magnesium sulphate and evaporated to dryness. The crude product is purified by chromatography on silica gel 60 (Nerck/petroleum ether:ethyl acetate=20:1 later 10:1); yield 27 g.

[0314] Rf=0.36 (petroleum ether: ethyl acetate=5:1)

EXAMPLE NO. CXII

[0315] 6-Chloro-5-methyl-3-nitro-2-(2-oxo-cyclohexyl)-pyridine 120

[0316] 20 g (95.7 nmuol) of 2,6-dichloro-5-methyl-3-nitro-pyridine are reacted with 13.3 mnl (95.7 mmol) of triethylamine and 14.5 g (95.7 mmol) of freshly distilled 1-pyrrolidino-cyclopentene at 20° C. in 200 ml of DMF under argon as a protective gas. After the starting material has disappeared according to thin-layer chromatography (silica gel/petroleum ether: ethyl acetate=4:1), 200 ml of 1 M hydrochloric acid are added and the mixture is diluted with about 600 ml of water. The precipitate which is deposited is filtered off with suction, dried over phosphonrs pentoxide in a high vacuum and purified by chromatography (silica gel 60/Merck/petroleum ether: ethyl acetate=2:1).

[0317] Rf=0.69 (petroleum ether: ethyl acetate=4:1)

EXAMPLE NO. CXIII

[0318] 2-Methyl-5,6,7,8-tetrahydro-δ-carboline 121

[0319] 2.8 g (10.4 mmol) of the compound from Example CXII are reacted on 0.5 g of palladium (5%) / carbon in 30 ml of THF under a hydrogen pressure of 3 bar for 18 h. The catalyst is then filtered off with suction and washed several times with methanol and dichloromethane. The filtrate is evaporated and dried in a high vacuum; yield: 2.1 g

[0320] Rf=0.53 (dichioromethane: ethanol=5:1)

EXAMPLE NO. CXIV

[0321] 3-Methyl-5,6,7,8-tetrahydro-α-carboline hydrochloride 122

[0322] 13.0 g (120.2 mmol) of 2-amino-5-methyl-pyridine are dissolved in 150 ml of ethanol and the solution is stirred with 60 ml of 2 M hydrochloric acid, evaporated to dryness and finally dried over sodium hydroxide and phosphorus pentoxide in a high vacuum. The product thus obtained is boiled under reflux in a water separator with 2.2 g (20.1 mmol) of 2-amino-5-methyl-pyridine and 11.4 g (50.0 mmol) of 2-hydroxy-cyclohexanone dimer in 120 ml of 1,2-dichlorobenzene for 6 h. 1 11.4 g (50.0 mmol) of 2-hydroxycyclohexanone dirner are then added again and the mixtue is boiled under reflux for a flrther 3 h. On cooling, a precipitate is deposited at 20° C. 150 ml of acetone are added, the mixure is cooled to 0 to 5° C. with stiring, and the precipitate is filtered off with suction and washed with cold ether. The product obtained is dried over phosphorus pentoxide in a high vacuum; yield 18 g.

[0323] Rf=0.29 (dichloromethane: ethanol=20:1)

[0324] The compounds of the following Table XIV are obtained in analogy to the procedure of Example No. XIX:

TABLE XIV
			Starting
Ex. No.	Heterocycle	Rf (solvent)	material
CXV	123	0.16 (C)
CXVI	124	0.37 (C)	Ex. No. CXIII
CXVII	125	0.17 (D)	Ex. No. CXIV

EXAMPLE NO. CXVIII

[0325] 1-Chloro-5,7-dimethyl-β-carboline 126

[0326] 10.2 g (49 mmol) of the compound from Example No. CXV are reacted at 125° C. for 24 h with 222 ml (2.4 mol) of phosphorus oxychloride and 155 μl of N,N-dimethyl-aniline. The mixture is poured into 1 l of ice water after cooling, then neutrrlized with aqueous sodium carbonate solution and exited several times with ethyl acetate. The organic phase is dried with magnesium sulphate, evaporated and freed from the residual solvent in a high vacuumn The crude product is purified by chromatography on silica gel 60 (Merck/dichloromethane);

[0327] yield: 4.3 g.

[0328] Rf=0.39 (dichloromethane: ethanol=20:1)

EXAMPLE NO. CXIX

[0329] 5,7-Dimethyl-β-carboline 127

[0330] 3.8 g (16.5 mmol) of the compound from Example CXVIII are reacted with 1.3 g of sodium hydrogen carbonate on 700 mg of palladium (10%)/carbon at a hydrogen pressure of about 3 bar and 20° C. for 10 d in 40 mnl of THF, 300 mg of palladium (10%)/carbon and 5 ml of methanol being added on every second day. The catalyst is then filtered off with suction through kieselguhr, washed with THF, boiled in methanol and dichloromethane and again filtered off with suction. The combined organic solutions are evaporated, and the residue is precipitated by stirring with ether and filtered off with suction. After vacuum dring, 3 g of product are obtained.

[0331] Rf=0.13 (dichloromethane: ethanol=20:1)

EXAMPLE NO. CXX

[0332] 5,6-Dimethyl- 1 -(pyrid-2-yl)-1 H-benzotriazole 128

[0333] 14.85 g (103 mmol) of 5,6dimethyl-1 H-benzotriazole are dissolved in 150 ml of anhydrous DMSO, reacted with 5 g (104 mnuol) of 50% strength sodium hydride (+40% paraffin oil) at 20° C. until evolution of hydrogen is complete, treated with 10 g (103 mmol) of 2-fluoro-pyridine and the mixture is boiled under reflux for 18 h. After cooling to 20° C., the mixture is made up to a volume of about 1 l with water, and the resulting precipitate is filtered off with suction and washed with water. The substance, which is dried over phosphorus pentoxide in a high vacuum, is purified by chromatography on silica gel 60 (Merck/dichloromethane to dichloromethane: ethanol=100:1);

[0334] yield: 10.6 g.

[0335] Rf=0.38 (dichloromethane: ethanol=50:1)

EXAMPLE NO. CXXI

[0336] 6,7-Dimethyl-α-carboline 129

[0337] 8.9 g (39.7 mmol) of the compound from Example No. CXX are slowly heated to 165° C. in 140 g of polyphosphoric acid under argon, the mixture being poured into 1.5 l of water and adjusted to pH=6-7 with 1 M aqueous sodium hydroxide solution before disappearance of the starting material (TLC checking/dichioromethane: ethanol=20:1). The precipitate obtained is filtered off with suction, washed with water, rapidly filtered off with suction, then washed with petroleum ether and filtered off with suction again. After vacuum drying, 1.8 g of product are obtained.

[0338] Rf=0.32 (dichloromethane: ethanol=20:1)

[0339] The compounds in Table XV are prepared in analogy to the procedure of Example No. XXI:

	TABLE XV
	Ex. No.	Rf (solvent)
	CXXII	130	0.56 (H)
	CXXIII	131
	CXXIV	132

[0340] The compounds in Table XVI are prepared in analogy to the procedure of Example No. XXVIII:

TABLE XVI
		Starting
		material
Ex. No.	Rf (solvent)	(Ex. No.)
CXXV	133	0.40 (H)	CXXII
CXXVI	134		CXXIII
CXXVII	135		CXXIV

[0341] The compounds of Table XVII are prepared analogously to the procedure of Example No. XXXV:

TABLE XVII
136
Ex. No.	Z	Position (o, m or p)	137	D	R10	Rf (solvent)	MS	Starting material Ex. No.
CXXVIII	138	p	—	H	Me	0.59 (G)	DCI: 359 (100%)	XIX
CXXIX	139	p	rac	cPent	Me	0.51 (D)		XXXIII
CXXX	140	p	rac	cPent	Me	0.22 (C)		XXXIII (Harman is commercially available from Aldrich).

[0342]

		Position						Starting material
Ex. No.	Z	(o, m or p)	{circle over (1)}	D	R10	Rf (solvent)	MS	Ex. No.
CXXXI	141	m	rac	cPent	Me	0.55 (D)		XIX and CXXV
CXXXII	142	p	rac	cPent	Me	0.21 (D)		CXVI and XXXIII
CXXXIII	143	p	rac	cPent	tBu			XXVIII and CXXI
CXXXIV	144	p	rac	cPent	tBu			XXVIII and CXVII
CXXXV	145	p	rac	cPent	tBu			XXVIII and CXIX
CXXXVI	146	p	rac	cPent	Me	0.13 (L)		XXXIII
CXXXVII	147	p	rac	Me	tBu	0.43 (L)		XIX
CXXXVIII	148	p	rac	Et	tBu	0.51 (L)		XIX
CXXXIX	149	p	rac	nPent	Et			XIX and CXXVII
CXL	150	p	rac	151	Et			XIX and CXXVI

[0343] The compounds of Table XVIII are prepared analogously to the procedure of Example Nos. LXI or LXXXI:

TABLE XVIII
152
								Preparation
		Position					Starting material	analogous to
Ex. No.	Z	(o, m or p)	{circle over (1)}	D	Rf (solvent)	MS	Ex. No.	Ex. No.
CXLI	153	p	—	H	0.56 (O)		CXXVIII	LXXXI
CXLII	154	p	rac	cPent	0.14 (G)		CXXIX	LXXXI
CXLIII	155	p	rac	cPent	0.50 (U)		CXXX	LXXXI
CXLIV	156	m	rac	cPent	0.14 (D)		CXXXI	LXXXI
CVL	157	p	rac	cPent	0.10 (D)		CXXXII	LXXXI
CVLI	158	p	rac	cPent	0.34 (C)		CXXXIII	LXI
CVLII	159	p	rac	cPent			CXXXV	LXI
CVLIII	160	p	rac	cPent	0.15 (C)		CXXXV	LXI
CIL	161	p	rac	cPent			CXXXVI	LXXXI
CL	162	p	rac	Et			CXXXVIII	LXI
CLI	163	p	rac	Me			CXXXVII	LXI
CLII	164	p	rac	nPent			CXXXIX	LXXXI
CLIII	165	p	rac	166			CXL	LXXXI

PREPARATION EXAMPLES

EXAMPLES 1, 2 and 3

[0344] 2-(S)- and 2-(R)-2-[4-(2,4-Dimethyl-5,6,7,8-tetrahydro-α-carbolin-9-yl)methyl-phenyl]-2-cyclopentyl-acetic acid N-[(R)phenylglycinolamide] 167

[0345] 3.00 g (7.2 mmol of the compound from Example LXII are dissolved in 70 ml of dichloromethae with 0.99 g (7.2 mmol) of (R)-phenylglycinol (Aldrich), and the solution is treated successively at 0° C. with 1.07 g (7.9 mmol) of 1-hydroxy-1 H-* benztriazole hydrate (Aldrich), 1.58 g (8.3 mmnol) of N′-(3-dimethylaniiopropyl)-N-ethycabodiimide hydrochloride (Aldrich) and 2 ml of triethylamine and then stirred at room temperature for 20 hours. The organc solution is extracted with aqueous ammonium chloride solution, with aqueous sodium hydrogen carbonate solution and with a buffer of pH=4 (ready-touse buffer solution, E. Merck, Darmstadt), dried with solid anhydrous sodium sulphate and evaporated.

[0346]

[0347] Yield of the diastereomer mnixtue: 3.50 g (Examnple 1).

[0348] The product mixtue is separated by chromatograhy (silica gel, dichloromethae: ethanol 50:1):

EXAMPLE NO. 2

[0349]

[0350] Diastereomer A [2(S)-diastereomer]: 1.23 g

[0351] Rf=0.18 (dichloromethae: ethanol=50: 1)

[0352] 1 H-NMR (d-DMSO, 250 MHz, TMS):δ=0.87 (M, 1 H), 1.19-1.63 (M, 6 H), 1.72 (M, 1 H), 2.45 (M, 1 H), 2.58 (S, 3 H), 2.79 (S, 3 H), 3.26 (D, 1 H), 3.44-3.53 (M, 2 H), 4.21-4.31 (M, 2 H), 5.63 (S, 2 H), 6.97-7.11 (M, 8 H), 7.20-7.28 (M, 3 H), 7.41 (M, 1 H), 7.54 (D, 1 H), 8.12 (D, 1 H), 8.24 (D, 1 H) ppm.

EXAMPLE NO. 3

[0353] Diastereomer B [2(R)-diastereomer]: 1.12 g

[0354] Rf=0.16 (dichloromethane: ethanol=50:1)

[0355] 1 H-NMR (d-DMSO, 250 M TMS): δ=0.84 (M, 1 H), 1.07-1.59 (M, 7 H), 2.34 (M, 1 H), 2.61 (S, 3 H), 2.80 (S, 3 H), 3.25 (D, 1 H), 3.43 (M, 2 H), 4.63-4.72 (M, 2 H), 5.66 (S, 2 H), 6.98 (S, 1 H), 7.13 (M, 2 H), 7.20-7.30 (M, 8 H), 7.43 (M, 1 H), 7.57 (D, 1 H), 8.12 (D, 1 H), 8.36 (D, 1 H) ppm.

[0356] The absolute configurations of the enantiomerically pure carboxylic acids 2-(S)- and 2-(R)-2-{4[(quinolin-2-yl)methoxy]phenyl}-2-cyclopentyl-acetic acid [cf. EP 509 359] are known, so the absolute configurations of the amides Ex. No. C1 and Ex. No. C2 prepared therefrom analogously to the procedure of Examples 1 and 2 can be derived. The 1H-NMR spectra of the two diastereomeric products (200 MHz, d6-DMSO, TMS for Exarple No. C1 and 250 MHz, d6-DMSO, TMS for Example No. C2/FIG. 1 +L) have significant differences in the aromatic region: the H signals of the phenyl radical of Ex. No. C1 are at about 7.1 ppm (3 H) and 7.3 ppm (2 H and the H signals of Ex. No. C2 are at about 7.3 ppm (5 H). This finding is applicable to the compounds of Examples 2 and 3 (FIG. 2 +L) and also to many other derivatives of this type.

[0357] The examples mentioned in Tables 1, 2 and 3 are prepared in analogy to the procedure of Examples 1, 2 and 3:

TABLE 1
168
				Rf	Starting material
Ex. No.	Z	D	1	(solvent)	*(Ex. No.)
4	169	cPent	rac	0.41/0.46 (E)	LXI
5	170	cPent	S	0.46 (E)	LXI
6	171	cPent	R	0.41 (E)	LXI
7	172	cHept	rac	0.26/0.29 (D)	LXIII
8	173	cHept	S	0.29 (D)	LXIII
9	174	cHept	R	0.26 (D)	LXIII
10	175	cHept	rac	0.20/0.24 (E)	LXIV
11	176	cHept	S	0.24 (E)	LXIV
12	177	cHept	R	0.20 (E)	LXIV
13	178	cHept	rac	0.35 (C)	LXV
14	179	cHept	S	0.35 (C)	LXV
15	180	cHept	R	0.35 (C)	LXV
16	181	cPent	rac	0.33/0.37 (C)	LXVI
17	182	cHept	rac	0.25/0.38 (C)	LXVII
18	183	cHept	S	0.38 (C)	LXVII
19	184	cHept	R	0.25 (C)	LXVII
20	185	cPent	rac	0.29 (A)	LXVIII
21	186	cHept	rac	0.23/0.28 (D)	LXIX
22	187	cHept	S	0.28 (D)	LXIX
23	188	cHept	R	0.23 (D)	LXIX
24	189	cHept	rac	0.10/0.18 (E)	LXX
25	190	cHept	S	0.18 (E)	LXX
26	191	cHept	R	0.10 (E)	LXX
27	192	cHept	rac	0.17/0.23 (B)	LXXXI
28	193	cHept	rac	0.12/0.15 (B)	LXXXIV
29	194	cPent	rac	0.28 (E)	LXXI
30	195	cPent	rac	0.29 (C)	LXXII
31	196	cPent	rac	0.24 (C)	LXXIII
32	197	cPent	rac	0.39/0.48 (C)	LXXIV
33	198	cPent	S	0.48 (C)	LXXIV
34	199	cPent	R	0.39 (C)	LXXIV
35	200	cHept	rac	0.23/0.29 (D)	LXXV
36	201	cPent	rac	0.26 (A)	LXXVI
37	202	cHex	rac	0.28/0.30 (D)	LXXVII
38	203	cHex	rac	0.21/0.23 (D)	LXXVIII
*(R)-Phenylglycinol is commercially available from Aldrich.

[0358]

TABLE 2
204
				Starting material
Ex. No.	1	Rf (solvent)	*(Ex. No.)
39	205	rac	0.42 (C)	LXI
40	206	R	0.42 (C)	LXI
41	207	S	0.42 (C)	LXI
*(S)-Phenylglycinol is commercially available from Aldrich.

[0359]

TABLE 3
208
Ex.					Rf	Starting material
No.	Z	D	X	1	(solvent)	(Ex. No.)
42	209	cHept	H	rac	0.39 (C)	Carboxylic acid: Ex. No. LXIII Amine from Aldrich
43	210	cHept	H	rac	0.78 (E)	Carboxylic acid: Ex. No. LXIV Amine from Aldrich
44	211	cPent	H	rac	0.34 (D)	Carboxylic acid: Ex. No. LXII Amine from Aldrich
45	212	cPent	H	(−)-ent*	0.34 (D)	Carboxylic acid: Ex. No. LXII Amine from Aldrich
46	213	cPent	H	(+)-ent*	0.34 (D)	Carboxylic acid: Ex. No. LXII Amine from Aldrich
47	214	cHept	H	rac	0.25 (C)	Carboxylic acid: Ex. No. LXV Amine from Aldrich
48	215	cHept	H	rac	0.42 (C)	Carboxylic acid: Ex. No. LXVII Amine from Aldrich
49	216	cHept	H	rac	0.45 (C)	Carboxylic acid: Ex. No. LXIX Amine from Aldrich
50	217	cHept	H	rac	0.71 (E)	Carboxylic acid: Ex. No. LXX Amine from Aldrich
51	218	cHept	H	rac	0.59 (B)	Carboxylic acid: Ex. No. LXXXI Amine from Aldrich
52	219	cHept	H	rac	0.40 (B)	Carboxylic acid: Ex. No. LXXXIV Amine from Aldrich
53	220	cHept	3-OH	rac	0.45 (D)	Carboxylic acid: Ex. No. LXV Amine Ref.: US 43 88 250
54	221	cHept	4-OH	rac	0.39 (A)	Carboxylic acid: Ex. No. LXV Amine: Ref.: C. Hartmann and J.P. Klinman, Biochemistry, 30, 4605 (1991)
55	222	cHept	2-OCH3	rac	0.15 (B)	Carboxylic acid: Ex. No. LXV Amine from Aldrich
56	223	cHept	3-OCH3	rac	0.37 (D)	Carboxylic acid: Ex. No. LXV Amine from Lancaster
57	224	cHept	4-OCH3	rac	0.24 (B)	Carboxylic acid: Ex. No. LXV Amine from Aldrich
58	225	cHept	2-O—CH2—CH═CH2	rac	0.51 (C)	Carboxylic acid: Ex. No. LXV Amine: Ex. No. II
59	226	cHept	3-CO2CH3	rac	0.73 (C)	Carboxylic acid: Ex. No. LXV Amine: Ref. F.M. Markwardt et al., Pharmazie 22, 465 (1967).
60	227	cHept	4-CO2CH3	rac	0.33 (B)	Carboxylic acid: Ex. No. LXV Amine: Ref.: M.G. Nair and C.M. Baugh, J. Org. Chem. 38, 2185 (1973).
61	228	cHept	3-CH3	rac	0.19 (B)	Carboxylic acid: Ex. No. LXV Amine from Aldrich
62	229	cHept	2-NO2	rac	0.39 (B)	Carboxylic acid: Ex. No. LXV Amine: Ref.: EP 373 891
63	230	cHept	3-NO2	rac	0.28 (B)	Carboxylic acid: Ex. No. LXV Amine from Aldrich
64	231	cHept	4-NO2	rac	0.21 (B)	Carboxylic acid: Ex. No. LXV Amine from Aldrich
65	232	cHept	2-Cl	rac	0.75 (D)	Carboxylic acid: Ex. No. LXV Amine from Aldrich
66	233	cHept	3-Cl	rac	0.71 (D)	Carboxylic acid: Ex. No. LXV Amine from Lancaster
67	234	cHept	4-Cl	rac	0.61 (D)	Carboxylic acid: Ex. No. LXV Amine from Aldrich
68	235	cPent	H	rac	0.28 (D)	Carboxylic acid: Ex. No. LXI Amine from Aldrich
*Resolution of enantiomers is carried out by means of HPLC (Chiralpak AD, length 250 nm, diameter 4.6 mm, particle size 10 μ, eleunt: 95% n-heptane + 5% ethanol (the latter containing 1% water and 0.2% trifluoroacetic acid)).

EXAMPLE 69

[0360] 2-(R,S)-2-[4-(2,4-Dimethyl-5,6,7, 8-tetrahydro-α-carbolin-9-yl)-methyl-phenyl]-2-cycloheptyl-acetic acid N2-hydroxybenz~l)amide 236

[0361] 0.60 g of the compound from Example 58 are boiled under reflux for 22 hours wAith 33 mg of palladium (10% on animal carbon) and 33 mg of paratoluenesulphonic acid monohydrate in 3 mnl of methaol and 0.6 ml of water under argon as a protective gas. If reaction is incomplete (TLC checking, diclhioromethane: ethanol =50:1). 33 mg of palladium (10% on animial carbon) and 33 mg of paratoluenesulphonic acid monohydaate are added once more and the mixtue is boiled under reflux for a fuirther 24 hours. The catalyst is filtered off hot with suction and washed Aith plenty of hot methaol, and the filtrae is evaporated. After drying in a high vacuum over phosphorus pentoxide, 0.52 g of product are obtained

[0362] Rf=0.33 (dichloromethane: ethanol=50:1)

EXAMPLE 70

[0363] 2-(R,S)-2-[4-(3-Hydroxymetyl-β-carbolin-9-yl)methyl-phenyl]-2-cyclo-pentyl-acetic acid N-(R)-phenylglycinolamide 237

[0364] 500 mg (0.868 mnol) of the compound from Example 31 are treated dropwise with 1.737 ml (1.737 mmol) of a 1 M lithium alurninium hydride solution in tetrahydrofuran under argon at 0° C. in 5 ml of anhydrous tethydrofiuran and stirred at about 20° C. for 4 h. The reaction mixture is treated cautiously with 5 ml of wvater and adjusted to a pH of about 2 using 2 M aqueous hydrochloric acid. The aqueous phase is extacted several times wNith diethyl ether and dichioromethane, dried with sodium sulphate and evaporated. The crude product is purified by chromatography on silica gel 60 (Merck, dichioromethane to dichworomethane: methanol 50:1).

[0365] Yield: 0.12 g

[0366] Rf=0.26 (dichioromethane: ethanol=20:1)

[0367] The compounds of Table 4 are prepared in analogy to the procedure of Example 70:

TABLE 4
238
Ex. No.	Y	1	Rf (solvent)	Starting material
71	4-CH2OH	rac	0.47 (C)	Ex. No. 60
72	3-CH2OH	rac	0.26 (C)	Ex. No. 59

EXAMPLE 73

[0368] 2 -(R,S)-2-[4-(2,4-Dimethyl-5,6,7,8-tetrahydro-α-carbolin-9-yl)-methyl-phenyl]-2-cycloheptyl-acetic acid N-(4-carboxybenzyl)amide 239

[0369] 0.325 g (0.55 mmol) of the compound from Example 60 is reacted at 60° C. with 0.5 ml of aqueous 2 M sodium hydroxide solution in 3 ml of methanol for 18 h. If the reaction is still not complete according to thin-layer analysis (solvent F), a flrther 0.5 ml of aqueous 2 M sodium hydroxide solution in 1 mnl of methanol is added and the mixture is then boiled under reflux for 24 h. The reaction mixture is cooled and adjusted to a pH of about 4 using 1 M hydrochloric acid, and the precipitate which is deposited is filtered off with suction, washed with water and petroleum ether: diethyl ether=5:1 and freed from the residual solvents in a high vacuum over phosphorus pentoxide.

[0370] Yield: 0.154 g

[0371] Rf=0.50 (dichloromethane: methanol: acetic acid=90:10:2)

EXAMPLE 74

[0372] 2-(R,S)-2-[4-(2,4-Dimethyl-5,6,7,8-tetrahydro-α-carbolin-9-yl)-methyl-phenyl]-2-cycloheptyl-acetic acid N-(3-carboxybenzyl)amide 240

[0373] The title compound can be prepared from the compound of Example 59 analogously to the procedure of Example 73.

[0374] Rf=0.27 (dichloromethane: ethanol=20:1)

[0375] The compounds shown in Tables 5, 6, 7, 8, 9 and 10 are prepared in analogy to the procedure of Example 1:

TABLE 5
241
	Ex. No.	Y	1	M.p.	Starting material
	75	3-OH	rac	177-178	Carboxylic acid:
					Ex. No. LXII
					Amine: US 43 88 250
	76	4-OH	rac	183-184	Carboxylic acid:
					Ex. No. LXII
					Amine: Ref.:
					C. Hartmann and
					J. P. Klinman,
					Biochemistry 30, 4605
					(1991)

[0376]

TABLE 6
242
Ex. No.	R5	Rf (solvent)	Starting material
77	243	0.20 (C)	Carboxylic acid: Ex. No. LXV Amine from Aldrich
78	244	0.12 (C)	Carboxylic acid: Ex. No. LXV Amine from Aldrich
79	245	0.19 (C)	Carboxylic acid: Ex. No. LXV Amine from Aldrich
80	246	0.24 (D)	Carboxylic acid: Ex. No. LXV Amine from Aldrich

[0377]

TABLE 7
247
Ex. No.	1	−R20	Rf (solvent)	Starting material
81	rac	248	0.10 (P)	Acid: Ex. No. LXXIX Amine from Aldrich
82	rac	249	0.28 (P)	Acid: Ex. No. LXXIX Amine from Aldrich

[0378]

TABLE 8
250
						Starting materia1
						a) Reference
Ex.				M.p. (° C.)		b) Distributor
No.	1	X	Y	Rf (solvent)	MS (FAB)	c) Synthesis from Ex. No.
83	rac	3-OCH3	4-OCH3	179	562 (100%)	Carboxylic acid:
				0.50 (A)	154 (80%)	c) Ex. No. LXI
						Amine from Aldrich.
84	rac	3-CH3	5-CH3	212	530 (100%)	Carboxylic acid:
				0.60 (B)		c) Ex. No. LXI
						Amine from Emka-Chemie.
85	rac	3-Cl	5-Cl	212	570 (100%)	Carboxylic acid:
				0.18 (M)	196 (50%)	c) Ex. No. LXI
						Amine from Maybridge.
86	rac	3-OH	4-OH	137	534 (100%)	Carboxylic acid:
				0.39 (A)	307 (60%)	c) Ex. No. LXI
						Amine from Aldrich.
87	rac	3-OCH3	4-OH	135	548 (80%)	Carboxylic acid:
				0.65 (A)	154 (100%)	c) Ex. No. LXI
						Amine from Aldrich.

[0379]

TABLE 9
251
			M.p.		Starting material
			(° C.)		a) Reference
Ex.			Rf		b) Distributor
No.	1	D	(solvent)	MS (FAB)	c) Synthesis from Ex.No
88	rac	iPr	210	506 (100%)	Caxboxylic acid:
			0.37/0.31	154 (60%)	Ex. No. LXXXII
			(A)
89	rac	iBu	—	520 (100%)	Carboxylic acid:
			0.30 (A)	154 (50%)	Ex. No. LXXX
*(R)-Phenylglycinol is commercially available from Aldrich.

[0380]

TABLE 10
252
			M.p. (° C.)	Starting material
Ex. No.	−Z	−R21	Rf (solvent)	from Ex. No.
90	253	254	188-189	LXXXIX
91	255	256	0.024 (P)	LXXXIX
92	257	258	207-208	XC
93	259	260	211-212	XC

[0381] The compounds of Table II are prepared analogously to the procedure of Example Nos. 1, 2 and 3:

TABLE 11
261
Ex.				M.p. (° C.)		Starting material
No.	Z	D	1	Rf (solvent)	MS (FAB)	from Ex. No.
94	262	cHept	S	0.23 (B)		27
95	263	cHept	R	0.17 (B)		27
96	264	cPent	S	0.29 (A)		20
97	265	cPent	R	0.29 (A)		20
98	266	cHex	S	0.23 (D)		38
99	267	cHex	R	0.21 (D)		38
100	268	iPr	S	208° C.	506 (100%) 154 (40%)	88
101	269	iPr	R	204° C.	506 (100%) 154 (40%)	88
102	270	iBu	S	182° C.		89
103	271	iBu	R	206° C.		89
104	272	cPent	rac	0.34 (C)		CV
105	273	cPent	rac	0.44 (E) 0.56		CVI
106	274	cPent	S	0.56 (E)	586 (100%) 154 (94%)	CVI
107	275	cPent	R	0.44 (E)		CVI
108	276	cPent	rac	0.26 (E) 0.31		CVII
109	277	cPent	S	0.55 (C)		CVII
110	278	cPent	R	0.57 (C)		CVII
111	279	cPent	rac	0.45 (C)		CVIII
112	280	cPent	rac	0.4 C		CIX
113	281	cPent	rac	0.37 C		CX
114	282	cPent	S	0.37 (C)		CX
115	283	cPent	R	0.37 (C)		CX
116	284	cPent	diaA	194° C.		81
117	285	cPent	diaB	137° C.	81

[0382] The compounds of Table 12 are prepared analogously to the procedure of Bxarnple Nos. 1, 2 and 3:

TABLE 12
286
Ex.			M.p. (° C.)		Starting material
No.	1	R22	Rf (solvent)	MS (FAB)	from Ex. No.
118	rac	287	0.82 (C)	574 (100%)	LXI
119	rac	288	0.57 (C) 0.62	576 (100%)	LXI
120	rac	289	0.43 (C) 0.48		LXI
121	rac	290	0.52 (C)		LXI
122	rac	291	0.47 (C)		LXI
123	rac	292	0.17 (D) 0.32		LXI
124	rac	293	0.43 (C)		LXI
125	rac	294	0.57 (C)		LXI
126	rac	295	0.41 (C)		LXI
127	rac	296	0.14 (C)		137
128	S	297	187° C.	548 (100%) 154 (80%) 137 (85%)	LXI

[0383] The compounds of Table 13 are prepard analogously to the procedure of Example No. 73:

TABLE 13
298
Exam-
ple					M.p. [° C.]	Starting material
No.	{circle over (1)}/{circle over (2)}	X	Y	Z	Rf (solvent)	from Ex. No.
129	rac/rac	H	H	H	0.15 (S)	118
130	rac/rac	H	OH	H	0.18 (T)	119
					0.24
131	rac/rac	H	H	OH	0.68 (S)	120
					0.76
132	rac/rac	OH	H	H	0.16 (T)	121
					0.24

[0384] The compounds of Table 14 are prepared analogously to the procedure of Example No. 70:

TABLE 14
299
Exam- ple No.	300	X	Y	Z	M.p. [° C.]Rf (solvent)	Starting material from Ex. No.
133	rac/rac	H	OH	H	0.30 (A)	119
134	rac/rac	H	H	OH	0.25 (A)	120
135	rac/rac	OH	H	H	0.33 (A)	121
136	rac/rac	H	OH	OH	0.23 (A)	122
137	rac/rac	H	H	NH2	0.31 (C)	125

EXAMPLE NO. 138

[0385] 2 -(R,S)-2-[4(2,4-Dimethyl-α-carbolin-9-yl)methyl-phenyl]-2-cyclopentyl-acetic acid N-[1-(R,S)-1-(4-acetamido-phenyl)-2-hydroxy-ethyl]amide 301

[0386] Part A

[0387] 0.60 g (1.10 nmmol) of the compound from Example No. 137 is treated Nitfl 192 μl (3.29 mmol) of triethylarmne in 10 ml of dichioromehane and then reacted at 0° C with 70 μl (0.99 mmol) of acetyl chloride. After a stirring time of 3 hours, in which the reaction temperature rises to 20° C., the mixture is shaken successively with 1 M hydrochloric acid, 0.1 M aqueous sodium hydroxide solution and water, and the organic phase is dried with magnesium sulphate and evaporated

[0388] Part B

[0389] The crude product thus obtained shows a double acetylation (631, 57%, M++H/653, 6%, M++Na) in the mass spectme (FAB). It is therefore reacted with 2 M sodium hydroxide solution at 20° C. for one hour in 6 ml of methanol. The pH is then adjusted to 2 using 1 M hydrochloric acid and the mixture obtained is extracted with ethyl acetate. The organic phase is washed with water until neutral, dried with magnesium sulphate and evaporated in vacuo. Drying in a high vacuum yields 0.28 g of product.

[0390] Rf=0.17 (Dichloromethane: ethanol=20:1)

EXAMPLE NO. 139

[0391] 2-(R,S)-2-[4(2,4-Dimethyl-α-carbolin-9-yl)-methyl-phenyl]-2-cyclopentyl-acetic acid N-[1 -(R,S)-1(4-acetamido phenyl)-2-acetoxy-ethyl]amide 302

[0392] If the comrpound from Example No. 137 is reacted w.ith 4 equivalents each of triethylamine and acetyl chloride analogously to Part A of the procedure from Farnle No. 139, the title compound is obtained.

[0393] Rf=0.56 Dichloromethane ethanol=20:1)

[0394] The compounds of Table 15 are prepared analogously to the procedure of Example No. 138:

TABLE 15
303
Example No.	304	R23	M.p. [° C.]Rf (solvent)	Starting material from Ex, No.
140	rac/rac	nBu	0.49 (A)	137
141	rac/rac	Et	0.81 (U)	137

EXAMPLE NO. 142

[0395] 2(S)2-[4-(2,4-Dimethyl-α-carbolin-9-yl)methyl-phenyl]-2-cyclopentyl-acetic acid N-[1-(R)-1-phenyl-2-acetoxy -ethyl]amide 305

[0396] 4.5 g (8.46 nimol) of the compound No. 2 are suspended in 300 ml of dichioromethane, treated with 2.05 ml (25.4 mmol) of pyridine and 1.82 ml (25.4 mmnol) of acet), chloride in 30 ml of dichloromethae and reacted at 20° C. for 20 hours. The rnxueis extrated witti buffer (Merck) of pH=2 and water, dried with sodium sulphate and evaporated. After precipitating by stirring with methanol and subsequently drying in a high vacuumn over phosphorus pentoxide, 3.6 g of product are obtained.

[0397] Rf=0.62 (Petrolewn ether: ethyl acetate=1:1)

[0398] The compounds of Table 16 are prepared analogously to the procedure of Example No. 142:

TABLE 16
306
Example		M.p. [° C.]	Starting material
No.	R24	Rf (solvent)	from Ex. No.
143	—Et	0.25 (D)	2
144	—CH2OAc	0.29 (D)	2
145	—CH2OCH2Ph	0.27 (D)	2
146	(CH2)7-Z-CH═CH—(CH2)7CH3	0.52 (D)	2
147	—(CH2)14—CH3	0.69 (G)	2
148	—Ph	0.65 (C)	2
149	307		2
150	-tBu	0.38 (C)	2

EXAMPLE NO. 151

[0399] 2-(S)-2-[4-(2,4-Dimethyl-α-carbolin-9-yl)methyl-phenyl]-2-cyclopentyl-thioaceticacid N-[1-(R)-1-phenyl-2-acetoxy-ethyl]amide 308

[0400] 1.5 g (2.6 mmol) of the compound from Example No. 142 are treated with 1.27 g (3.13 mmol) of 2,4bis-(4-methoxyphenyl)-1,3dithia-2,4-diphosphetane-2,4- di-sulphide (Lawesson's reagent) in 50 ml of dioxane and boiled under reflux for 5 hours. The reaction mixture is evaporated to drmess in vacuo and purified by chromiatogrpy on silica gel MATREX™ silica Si (Amicon, Gce Company/20 μ/MPLC column/ dichloromethane: ethanol=100:1); yield: 665 mg.

[0401] Rf=0.53 (Petroleumn ether: ethyl acetate=2:1)

[0402] MS (FAB): m/e=612 (4%, [M+Na]+), 590 (100%, [M+H]+), 529 (19%, M+-AcOH).

EXAMPLE 152

[0403] 2-(S)-2-[4-(2,4-Dimethyl-α-carbolin-9-yl)methyl-phenyl]-2-cyclopentyl-acetic acid N-[1-(R)1-phenyl-2-[2-hydroxy-acet)-oxy ]-ethyl]amide 309

[0404] 1.45 g (2.13 mmol) of the cornpound from Example No. 145 are hydrogenated with hydrogen on palladium (5% on animal carbon) at 20° C. and normal pressure in 100 ml of THF. After 18 hours, the mixture is filtered off with suction through kieselguhr, washed several times wvith methanol and dichloromethane, and the combined organic solutions are evaporated. The solid residue is stirred with pentane, filtered off with suction and freed om the residual solvent in a high vacuum.

[0405] Rf=0.31 (Petroleum ether: ethyl acetate=1:1)

EXAMPLE NO. 153

[0406] 2(S)-2-[4-(2,4-Dimethyl-α-carbolin-9-yl)methyl-phenyl]-2-cyclopentyl-thoaceticacid N-[1(R)-1-phenyl-2-hydroxyethyl]-amide 310

[0407] The title compound is prepared at 20° C. from the compound of Example No. 151 in DME as a solvent analogously to the synthesis procedure from Example No. 73.

[0408] Rf=0.24 (Dichloromeffime: effinol=50:1)

EXAMPLE NO. 154

[0409] 2-[4-(2,4-Dimethyl-α-carbolin-9-yl)-methyl-phenyl]-2-cyclopentyl-acetic acid N-[1-(thien-2-yl)-1-methoxycarbonyl-methyl]-amide 311

[0410] The title compound is prepared from the compound of Example No. LXII and (R,S)——(thien-2-yl)—glycine methyl ester analogously to the synthesis procedure of Example Nos. 1, 2 and 3.

[0411] Rf=0.67 (Dichloromethane: ethanol=20:1)

EXAMPLE NO. 155

[0412] 2-[4-(2,4-Dimethyl-α-carbolin-9-yl)-methyl-phenyl]-2-cyclopentyl-acetic acid N-[1-thien-2-yl)-2-hydroxy-ethyl]-amide 312

[0413] The title compound is prepared from the compound of Example No. 154 analogously to the synthesis procedure of Example No. 70.

[0414] Rf=0.21 (Dichloromethane: ethanol=50:1)

EXAMPLE NO. 156

[0415] 2-(S)-2-[4-(2,4-Dimethyl-α-carbolin-9-yl)methyl-phenyl]-2-cyclopentyl-acetic acid N-[1-(R)-1-phenyl-2-(2,4,6-trimethyl-benzoyl-oxy)ethyl]-amide 313

[0416] The compound is prepared from Example No. 2 is reacted to give the title compound analogously to the procedure of Example No. 142.

[0417] Rf=0.26 (Mobile phase D)

EXAMPLE 157

[0418] 1-(R,S)-1-Phenyl-2-triphenylmethyloxy-ethyl 2-(R,S)-2-[4-(2,4-dimethyl-α-carbolin-9-yl)methyl-phenyl]-2-cyclopentyl-acetate 314

[0419] 1.0 g (2.42 mmol) of the compound from Exmle LXI is reacted with 1 ml (7.27 mmol of triethylamidne and 206 μl (2.67 mmol) of mesyl chloride in 30 ml of DMF at −30° C. for 2 h, then traed dropwise with a solution of 1.1 g (2.9 mmol) of the compound from Example No. CXI and 296 mg (2.42 mmol) of DMAP in 10 ml of DMF and stirred for ab~out 20 h while graually warming to 20° C. For working up, the mixture is stirred into ether/w,ater, the phases are separated, and the organic phase is extracted with aqueous 1 M sodium hydroxide solution and washed with w,ater. The organic phase is dried with manaesium sulphate and evaporated - finally in a high vacuum; yield: 1.0 g.

[0420] Rf=0.44 (Petoleum ether: ethyl acetate=5:1)

EXAMPLES 158 and 159

[0421] 1-(R,S)-1-Phenyl)-2-triphenylmethyloxy-ethyl [2-(R,S)-2-[4-(2,4-dimethyl-α-carbolin-9-yl)methyl-phenyl]-2-cyclopentyl-acetate 315

[0422] 1.0 g (1.29 mmnol) of the compound from ale No. 157 is stirred with 5 ml of trifluoroacetic acid in 10 ml of TW and 5 ml of water at 20° C. for 48 h. The mixture is then stirred with 300 ml of ether and 200 ml of aqueous sodium hydrogen carbonate solution, the phases are separated after evolution of carbon dioxide has subsided and the organic phase is extracted with buffer of pH=7 (Merck) and dried with magnesium sulphate. After evaporating the solvents, a crude product is obtained which is purified by chromatogphy on silica gel (Merck/petroleum ether: ethyl acetate=5:1) and separated into the diastereomers.

[0423] Racemic diastereomer A)

[0424] Yield: 300 mg

[0425] Rf=0.54 (Petroleum ether: ethyl acetate=2:1)

[0426] Racemic diastereomer B)

[0427] Yield: 320 mg

[0428] Rf=0.42 (Petroleum ether: ethyl acetate 2:1)

[0429] The compounds of Table 17 are prepared analogously to the procedure of Exaimp~eNos. 1, 2 and 3:

TABLE 17
316
Ex. No.	Z	Position (o, m or p)	317	D	Rf (solvent)	MS	Starting material Ex. No.
160	318	p	—	H	0.30 (C)	FAB: 464 (100%)	CXLI
161	319	p	rac	cPent	0.35 (C)	FAB: 504 (95%)	CXLII
162	320	p	S	cPent	0.35 (C)		CXLII
163	321	p	R	cPent	0.35 (C)		CXLII
164	322	p	rac	cPent	0.23/(C) 0.25	FAB: 518 (51%)	CXLIII
165	323	p	R	cPent	0.29 (C)		CXLIII
166	324	p	S	cPent	0.25 (C)		CXLIII
167	325	m	rac	cPent	0.40 (C)	FAB: 532 (100%)	CXLIV
168	326	p	rac	cPent	0.26/0.22 (D)	FAB: 518 (100%)	CVL
169	327	p		cPent	0.26 (D)		CVL
170	328	p		cPent	0.22 (D)		CVL
171	329	p	rac	cPent	0.37 (C)		CVLI
172	330	p	rac	cPent			CVLII
173	331	p	rac	cPent	0.19 (C)	FAB: 532 (100%)	CVLIII
174	332	p	rac	cPent			CIL
175	333	p		cPent			CIL
176	334	p		cPent			CIL
177	335	p	rac	Et			CI
178	336	p	rac	Me			CLI
179	337	p	rac	nPent			CLII
180	338	p	diaA	nPent			CLII
181	339	p	diaB	nPent			CLII
182	340	p	rac	341			CLIII
183	342	p	diaA	343			CLIII
184	344	p	diaB	345			CLIII

EXAMPLE 185

[0430] 2-(R,S)-2-[4-(2,4-Dimethyl-α-carbolin-9-yl-methyl-phenyl]-2-cyclopentyl-acetic acid [N-benzyl, N-benzoyl]-amide 346

[0431] 2.0 g (4.8 mmol) of the compound from Example No. LXI are reacted with 0.74 ml (5.3 mmol) of triethylamine and 0.41 ml (5.3 mmol) of mesyl chloride at −30° C. in anhydrous DMF for 1 h. A solution of 1.07 g (5.1 nunol) of N-benzyl-benznide and 1.42 ml (10.2 mmol) of triethylamine in 10 ml of anhdrous DMF is then added dropnise at −30° C. and stirred for 16 h while gradually warming to 20° C. The reaction mixture is stirred with ether and water, the phases are separated and the aqueous phase is washed after setting a pH of 4 and 7 in each case. The combined organic solutions are evaporated and purified by chromiatography on silica gel 60 (Merck / first dichloromethane: ethanol =60:1; then petroleum ether: ethyl acetate=4:1).

[0432] Rf=0.58 (Petroleum ether: ethyl acetate=2:1)

EXAMPLE 186

[0433] 2-(R,S)-2-[4-(2,4-Dimethyl-α-carbolin-9-yl)methyl-phenyl]-2-cyclopentyl-acetic acid [N-benzoyl]-amide 347

[0434] 2.0 g (3.3 mmol) of the compound from Example No. 185 are reacted at 20° C. under a hydrogen pressure of about 1 bar on 2 g of palladium on animal carbon (5%) in dioxane for about 40 h. The mixture is then filtered off with suction through a Seitz filter and washed with dioxane, and the filtrate is evaporated. The crude product is precipitated by stirring with methanol at 60° C. and is filtered off with suction at 20° C., washed with cold methanol and dried over phosphorus pentoxide in vacuo.

[0435] Rf=0.49 (Petroleum ether: ethyl acetate=2:1)

EXAMPLE 187

[0436] 2-(R,S)-2-[4-(2,4Dimethyl-α-carbolin-9-yl)-methyl-phenyl]-2-cyclopentyl-acetic acid [N-(1-(R,S)-1-phenyl-1-ethoxycarbonyl-methyl]-amide 348

[0437] The compound from Example No. LXI is reacted to give the title compound analogously to the proceure of Example Nos. 1, 2 and 3.

EXAMPLE 188

[0438] 2(R,S)-2-[4-(2,4-Dimethyl-α-carbolin-9-yl)-methyl-phenyl]-2-cyclopentyl-acetic acid [N-(1-(R,S)-1-phenyl-1-carboxy-methyl]-amide 349

[0439] The compound from Example No. 187 is reacted to give the title compoud analogously to the proceure of Example No. 73.

EXAMPLE 189

[0440] 1-1-(R,S)-2-hydroxy-phenyl-ethyl2-(R,S)-2-[4-(2,4-Dimethyl-α-carbolin-9-yl)methyl-phenyl]-2-cyclopentyl-acetate 350

[0441] 1 g (2.42 mmol) of the compound from Example No. LXI is reacted with, 1 ml (7.27 mmol) of triethylamine and 206 μl (2.67 mmol) of mesyl chloride for 1 h in 30 ml of DMF at −30° C. A solution of 1-(R,S)-1-phenyl-2-hydroxy-thioethanol in 10 ml of DMF is then added dropnvise at the tempraue mentioned and the mixure is stirred for a futirher hour. For wvorking up, the reaction mixture is stirred into ether and aqueous sodium hydrogen cabnate solution. The organic phase is washed with buffer pH=2 and then pH=7, dried withi magtesitun sulphate and evaporated. The crude product is purified on silica gel 60 (Merck/petroleum ether: ethyl acetate=5:1); yield: 660 mg

[0442] Rf=0.58 (Petroleum ether: ethyl acetate=2:1)

Claims

1. Cycloalkano-indole and -azaindole derivatives of the general formula (I)

2. Cycloalkano-indole and -azaindole derivatives of the formula according to claim 1wherein R1 and R2, including the double bond connecting them, together form a phenyl or pridyl ring or a ring of the formula 353wherein R8 denotes hydrogen or straightchain or branched alkyl having up to 3 carbon atoms, R3 and R4 including the double bond connecting them, together formn a phenyl ring or a cyclopentene, cyclohexene, cycloheptene, cyclooctene, oxocyclopentene, oxocyclohexene, oxocycloheptene or oxocyclooctene radical, or ring systems mentioned under R1/R2 and R3/R4 optionally being substituted up to 2 times by identical or different fluorine, chlorine, bromine, trifluoromethyl, carboxyl or hydroxyl substituents, by straight-chain or branched alkoxy or alkoxycarbonyl each having up to 4 carbon atoms or by straightchain or branched alkyl having up to 4 carbon atoms, which, in nun, can be substituted by hydroxyl- or by staiight-chain or branched alkoxy having up to 3 carbon atoms, D represents hydrogen, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooct),l or straight-chain or branched aikyl having up to 10 carbon atoms, E represents the —CO— or —CS— group, L represents an oxygen or sulphur atom or represents a group of the formula —NR9, wherein R9 denotes hydrogen or straight-chain or branched allyl having up to 5 carbon atoms, which is optionally substituted by hydroxyl or phenyl, R5 represents phenyl, pyridyl, fIryl, thienyl or iridazolyl, each of vhich is optionally substituted up to 2 times by identical or different nitro, carboxyl, fluorine, chlorine, bromine or cyano substituents, by straight-chain or branched alkenyl or alkoxy carbonyl each having up to 4 carbon atoms or by straighthain or branched alkyl having up to 5 carbon atoms, which is optionally substituted by hydroxyl, carboxyl or by straiht-chain or branched alkoxy or alkoxycarbonyl each having up to 5 carbon atoms, and/or the cycles are optionally substituted by a group of the formula —OR10 or —NR11R12, wherein R10 denotes hydrogen or staight-chain or branched alkyl or alkenyl each having up to 4 carbon atoms, R11 and R12 are identical or different and denote phenyl, hydrogen or straight-chain or branched allVI having up to 5 carbon atoms or denote straight-chain or branched acyl having up to 6 carbon atoms, which is optionally substituted by a group of the formula —NR13R14, wherein R13 and R14 are identical or different and denote hydrogen or straiht-hain or branched acyl having up to 6 carbon atoms, R6 represents hydrogen, carboxyl or straight-chain or branched alkoxycarbonyl having up to 4 carbon atoms, or represents straight-chain or branched alkyl having up to 5 carbon ators, which is optionally substituted by hydroxyl or by a group of the formula —O—CO—R15, wherein R15 denotes phenyl which is optionally substituted up to 3 times by identical or different fluorine, chlorine, bromine or hydroxyl substituents or by straight-chain or branched alkyl having up to 4 carbon atoms, or straight-chain or branched alkyl or alkenyl each having up to 20 carbon atoms, each of which is optionally substituted by a soup of the formula —OR16, wherein R16 is hydrogen, benzyl, triphenylmethyl or straight-chain or branched acyl having up to 5 carbon atoms, R7 represents hydrogen or R6 and R7 together represent the group of the formula=O, if appropriate in an isomeric form, and their salts.

3. Cycloalano-indole and -azaindole derivatives of the formula according to claim 1wherein R1 and R2, including the double bond connecting therm, together form a phenyl or pyridNl ring or a ring of the formula 354wherein R8 denotes hydrogen or methyl, R3 and R4including the double bond connecting them, together form a phenyl ring or a cyclopentene, cyclohexene, cycloheptene, cyclooctene, oxocyclopentene, oxocyclohexene, oxocycloheptene or oxocyclooctene radical; or ring systems mentioned under R1/R2 and R3/R4 optionally being substituted up to 2 timnes by identical or different fluorine, chlorine, brornine, trifluoromethyl, carboxyl or hydroxyl substituents, by straight chain or branched alkoxy or alkoxycarbonyl each having up to 3 carbon atoms or by straghtehin or branched alkyTl having up to 3 carbon atoms, whch, for its prt can be substite by bydroxyl, methoxy or ethoxy, D represents hydrogen, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl or straiht-chain or branched alkyl having up to 6 carbon atoms, E represents the —CO— or —CS— group, L represents an oxygen or sulphur atom or represents a group of the formula —NR9, wherein R5 denotes hydrogen or straight-chain or branched alkyl having up to 4 cawbon atoms, which is optionally substituted by hydroxyl or phenyl, R5 represents phenyl, pyridyl or thienyl, each of which is optionally substituted up to 2 times by identical or different nitro, carboxyl, fluorine, chlorine, bromine or cyano substituents, by straight-chain or branched alkenyl or alkoxycarbonyl each having up to 3 carbon atoms or by straight-chain or branched alkyl having up to 4 carbon atoms, which is optionally substituted by hydroxyl, carboxyl or by straight-chain or branched alkoxy or alkoxycarbonyl each having up to 4 carbon atoms, and/or the cycles are optionally substituted by a group of the formula —OR10 or —NR11R12, wherein R10 denotes hydrogen or straight-chain or branched alkyl or alkenyl-each having up to 3 carbon atoms, R11 and R12 are identical or different and denote phenyl, hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms or denote straight-chain or branched acyl having up to 5 carbon atoms, w,vhich is optionally substituted by a group of the formula —NR13R14, wherein R13 and R14 are identical or different and denote hydrogen or 5 staght-chain or branched acyl having up to 5 carbon atoms, R6 represents hydrogen, carboxyl or stght-chain or branched alkoxycarbonyl having up to 3 carbon atoms, or represents straight-chain or branched alkyl having up to 4 carbon atoms, eNich is optionally substituted by hydroxyl or by a goup of the fornula —O—CO—R15, wherein R15 denotes phenyl which is optionally substituted up to 3 times by identical or different straight-chain or branched allkl having up to 3 carbon atoms, or denotes straight-chain or branched alkyl or alkenyl each halving up to 19 carbon atoms, each of which is optionally substituted by a group of the formula —OR16, wherein R16 denotes hydrogen, benzyl, triphenylmethyl or stight-chain or branched acyl having up to 4 carbon atoms, R7 represents hydrogen or R6 and R7 together represent the group of the formula =O, if appropriate in an isomeric form, and their salts.

4. Cycloalkano-indole and -azaindole derivatives according to claim I wherein such compound is 2-[4-(2,4-dimethyl-5,6,7,8-tetrahydro-α-carboline-9-yl)methyl-phenyl]-2-cyclopenthyl-acetic acid N-[(R)-phenylglycinolamide] of a formula

5. Cycloalkano-indole and -azaindole derivatives according to claim 1 wherein such compound is 2-[4-(2,4-dimethyl-α-carboline-9-yl)methyl-phenyl]-2-cyclopenthyl-acetic acid N-[(R)-phenylglucynolam ide] of the formula

6. Cycloalkano-indole and -azaindole derivatives according to claim 1 wherein suchcompound is1-(R,S)-1-Phenyl)-2-triphenylmethyloxy-ethyl[2-(R,S)-2-[4-(2,4-dimethyl-α-carbolin-9-yl)-methyl-phenyl]-2-cyclopentyl-acetate of the formula

7. Cycloalkano-indoles and -azaindoles according to clain 1 wherein such compound is 2-(R,S)-2-[4-(2,4-Dimethyl-α-carbolin-9-yl)-methyl-phenyl]-2-cyclopentyl-acetic acid [N-(1-(R,S)-1-phenyl-1carboxy-methyl]-amide of the formula

8. A composition for the treatment of ateroscleroses comprising an amount effective therefor of a compound or salt thereof according to claim 1 and a pharmacologically ecaptable diluent.

9. The method of treating ateroscleroses in a pationt in need thereof which comprises atministering to such patient an amount effective therefor of a compound or salt thereof according to claim 1.